International Journal of Multidisciplinary Engineering in Current Research - IJMEC
Volume 10, Issue 5, May-2025, http://ijmec.com/, ISSN: 2456-4265

Fast-Acting Solutions: A Comprehensive Review Of Immediate Release Oral Contraceptive Dosage Forms

Adesh S. Wankhade 1* Prof. Unmesh M. Joshi 2, Dr. Aijaz A. Sheikh 3, Dr. K. R. Biyani 4

[1]Department of pharmaceutics, Anuradha College of Pharmacy Chikhali ,Maharashtra ,India.

[2] Associate professor, M.Pharm , Department of pharmaceutics ,Anuradha College of Pharmacy Chikhali, Maharashtra ,India

[3] HOD, Anuradha College of Pharmacy Chikhali, Maharashtra ,India

[4] Principal, Anuradha College of Pharmacy Chikhali, Maharashtra ,India

ABSTRACT

This comprehensive review explores the advancements and challenges associated with immediate release (IR) oral contraceptive dosage forms, which are pivotal in modern contraceptive therapy. Oral contraceptives, including combined oral contraceptives (COCs) and progestin-only pills (POPs), are widely utilized for their efficacy in preventing pregnancy through hormonal modulation. The evolution of these formulations has led to the development of low-dose and ultra-low-dose regimens that minimize adverse effects while maintaining contraceptive effectiveness. IR dosage forms are designed to ensure rapid disintegration and absorption of active pharmaceutical ingredients (APIs), achieving peak plasma concentrations within 1-2 hours post-ingestion. This rapid onset is crucial for effective ovulation suppression, particularly in emergency contraception scenarios. The review highlights the importance of excipient selection, including superdisintegrants and solubilizing agents, which enhance the bioavailability and dissolution rates of poorly soluble APIs like ethinylestradiol and levonorgestrel.Despite their advantages, IR formulations face challenges such as the need for strict adherence to dosing schedules and the impact of first-pass metabolism on bioavailability. The review also discusses regulatory considerations, including quality control measures and bioequivalence studies, which are essential for ensuring the safety and efficacy of these contraceptives. Furthermore, it identifies knowledge gaps and proposes future directions for optimizing IR formulations to improve user convenience and therapeutic outcomes in oral contraceptive regimens.This review serves as a valuable resource for healthcare professionals, researchers, and pharmaceutical developers aiming to enhance the effectiveness and accessibility of oral contraceptive therapies.

Key Words : Oral Contraceptives, Excipient Selection, Solubilizing Agents, Drug Absorption, Contraceptive Efficacy.

1. INTRODUCTION

Oral contraceptives, commonly known as birth control pills, are among the most widely used methods of reversible contraception globally. These medications primarily function through the modulation of female reproductive hormones to prevent ovulation, alter cervical mucus viscosity, and hinder endometrial implantation (1). They are categorized into two main types: combined oral contraceptives (COCs), which contain both estrogen (typically ethinylestradiol) and a

progestin, and progestin-only pills (POPs), which contain only a progestin such as norethindrone or levonorgestrel (2). Since their introduction in the 1960s, oral contraceptives have undergone significant evolution, transitioning from high-dose formulations to more refined low-dose and ultra-low-dose regimens, reducing adverse effects while maintaining efficacy (3). Their widespread adoption is attributed to their ease of administration, non-invasiveness, and additional non-contraceptive benefits such as menstrual regulation, acne control, and reduced risk of certain cancers (4). According to the World Health Organization (WHO), oral contraceptives are included in the Model List of Essential Medicines, reflecting their importance in public health systems worldwide (5). Despite their popularity, their effectiveness relies heavily on daily compliance, and missed doses can significantly reduce contraceptive efficacy, increasing the risk of unintended pregnancy. Immediate release (IR) dosage forms are designed to disintegrate and release their active pharmaceutical ingredients (APIs) quickly after oral administration. In the context of oral contraceptives, immediate release tablets are the standard delivery form, ensuring rapid absorption and consistent plasma hormone levels, which are critical for ovulation suppression (6). These formulations are engineered to maximize bioavailability by ensuring the drug dissolves promptly in the gastrointestinal tract, typically within 30 minutes of ingestion (7). The pharmacokinetics of IR oral contraceptives show rapid systemic absorption, usually achieving peak plasma concentrations within 1–2 hours for both ethinylestradiol and progestins like levonorgestrel (8). This rapid onset is particularly vital in start-of-cycle dosing, emergency contraception, and for maintaining hormonal consistency in daily regimens. Immediate release formulations are also advantageous in terms of manufacturing and patient acceptability, as they are generally small in size, easy to swallow, and cost-effective to produce. Moreover, IR tablets facilitate fixed-dose combinations, allowing multiple hormones to be administered in a single pill, optimizing treatment adherence and hormonal synergy (9). Despite these advantages, IR forms also present challenges such as shorter duration of action, necessitating strict adherence to daily intake schedules, and variability in absorption due to food or gastrointestinal conditions. This comprehensive review aims to explore the scientific, technological, and regulatory aspects of immediate release dosage forms used in oral contraceptive therapy. Immediate-release (IR) oral contraceptive tablets are designed to deliver active pharmaceutical ingredients (APIs) rapidly upon administration, ensuring timely contraceptive efficacy. The formulation of these tablets involves selecting appropriate excipients that facilitate quick disintegration and dissolution. Excipients such as sodium starch glycolate and croscarmellose sodium serve as superdisintegrants, enhancing the tablet's breakdown in the gastrointestinal tract. Additionally, the choice of binder and filler is crucial to maintain tablet integrity while ensuring rapid release. Common hormones used in IR oral contraceptives include ethinylestradiol (EE) and levonorgestrel (LNG). Upon ingestion, these hormones are absorbed into the bloodstream, exerting their effects by inhibiting ovulation and altering cervical mucus to prevent sperm entry. The pharmacokinetic profiles of these hormones are characterized by their absorption rates, peak plasma concentrations, and elimination half-lives. For instance, EE has a half-life of approximately 13–27 hours, while LNG's half-life ranges from 24 to 36 hours. Understanding these profiles is essential for

determining dosing schedules and ensuring contraceptive efficacy. The clinical benefits of IR formulations include rapid onset of action and ease of use, which can enhance patient compliance. However, limitations such as shorter duration of action and potential for higher peak plasma concentrations may necessitate strict adherence to dosing schedules to maintain efficacy and minimize side effects. Recent advancements in excipient technologies have significantly improved the performance of IR oral contraceptives. For example, the incorporation of mesoporous silica as a carrier in amorphous solid dispersions has enhanced the solubility and dissolution rates of poorly soluble APIs. Additionally, innovations in tablet engineering, such as the development of bilayered tablets, allow for the combination of immediate and sustained release profiles within a single dosage form, offering flexibility in treatment regimens. These technological advancements contribute to more efficient drug delivery and improved patient outcomes. Regulatory considerations for IR oral contraceptive tablets encompass quality control, bioequivalence, and patient adherence strategies. Quality control measures include dissolution testing to ensure that the tablet disintegrates and releases the API within the specified time frame, as well as stability studies to assess the formulation's consistency under various environmental conditions. Bioequivalence studies are conducted to compare the pharmacokinetic profiles of generic and reference formulations, ensuring therapeutic equivalence. Patient adherence strategies involve providing comprehensive information about the correct usage of the contraceptive, implementing reminder systems, and considering extended or continuous regimens to reduce the likelihood of missed doses. These regulatory considerations are essential to ensure the safety, efficacy, and acceptability of IR oral contraceptive tablets. The review also aims to identify knowledge gaps and propose future directions for optimizing IR formulations to further improve efficacy, safety, and user convenience in oral contraceptive regimens.

2. CLASSIFICATION AND TYPES OF ORAL CONTRACEPTIVE DRUGS

Oral contraceptive drugs are broadly classified based on their hormonal composition and therapeutic indications. The two principal categories are progestin-only pills (POPs) and combined oral contraceptives (COCs). Understanding their pharmacology, mechanism of action, and relevance to immediate release (IR) formulations is essential for optimizing contraceptive therapy.

2.1 Progestin-Only Pills

Progestin-only pills, often referred to as “mini-pills,” contain a single active hormone—a synthetic progestin, such as norethindrone, desogestrel, or levonorgestrel. Unlike combined formulations, POPs do not contain estrogen and are therefore preferred in individuals who are estrogen-intolerant, breastfeeding, or at risk for cardiovascular complications (10). These formulations work primarily by thickening cervical mucus, thereby inhibiting sperm penetration. Some POPs, particularly those containing desogestrel at higher doses, can suppress ovulation, although this is not consistent across all progestin types (11). POPs are typically formulated as immediate release tablets to ensure rapid and consistent plasma levels, given their short half-lives and narrow therapeutic windows. A key challenge with POPs is the requirement for strict adherence, as missing a dose by more than 3 hours may compromise contraceptive effectiveness (12). This underscores

the need for high-performance IR formulations with robust dissolution profiles and reliable bioavailability.

2.2 Combined Oral Contraceptives (COCs)

COCs contain both an estrogen (usually ethinylestradiol) and a progestin (such as levonorgestrel, norethindrone acetate, or drospirenone). These formulations exert multiple effects on the reproductive axis, providing a more comprehensive contraceptive mechanism compared to POPs (13). The estrogen component suppresses the secretion of follicle-stimulating hormone (FSH), preventing follicular development, while the progestin inhibits the luteinizing hormone (LH) surge, thereby blocking ovulation. Additionally, they alter the endometrial lining and cervical mucus, further reducing the likelihood of fertilization and implantation (14). COCs are widely used due to their high efficacy (failure rates <1% with perfect use), regular menstrual bleeding patterns, and non-contraceptive benefits, such as acne reduction and lower risk of ovarian and endometrial cancers (15). These tablets are almost universally produced as immediate release formulations to ensure rapid hormone absorption, essential for consistent endocrine suppression throughout the cycle.

2.3 Mechanism of Action

Both POPs and COCs utilize hormonal modulation to prevent pregnancy. The mechanisms differ slightly based on the composition but broadly include the following pathways. Combined oral contraceptives (COCs) and progestin-only pills (POPs) are widely used hormonal contraceptives that function through multiple mechanisms to prevent pregnancy. Their primary actions include suppressing ovulation, altering cervical mucus, modifying the endometrial lining, and affecting fallopian tube motility. COCs, which contain both estrogen and progestin, suppress ovulation by inhibiting the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. This suppression prevents the release of an egg from the ovary. Additionally, COCs increase the viscosity of cervical mucus, creating a barrier that impedes sperm penetration. The endometrial lining becomes less receptive to implantation due to the hormonal effects, and there is a reduction in tubal motility, which can affect the transport of ova and sperm. POPs, which contain only progestin, primarily prevent pregnancy by thickening cervical mucus, thereby hindering sperm movement. While ovulation suppression occurs in some cycles, it is not consistent across all users. The progestin in POPs also induces changes in the endometrium, making it less suitable for embryo implantation. Furthermore, progestins can slow the movement of the ovum through the fallopian tubes, potentially reducing the likelihood of fertilization. Both COCs and POPs are effective contraceptive methods due to their combined actions on the reproductive system. However, their efficacy can be influenced by factors such as adherence to the dosing schedule and individual physiological responses. Understanding these mechanisms is crucial for healthcare providers to offer appropriate contraceptive options tailored to individual needs. Immediate release dosage forms play a pivotal role in facilitating these mechanisms by ensuring quick systemic absorption and timely plasma peaks, especially important for progestins with short half-lives.

2.4 Selection Criteria for Immediate Release Formulations

Formulating an oral contraceptive as an immediate release tablet is guided by several criteria.

Immediate-release (IR) oral contraceptive tablets are well-suited for specific hormonal drugs based

on a combination of pharmacokinetic properties, therapeutic needs, patient-centered considerations, and regulatory expectations. Hormonal drugs like desogestrel, which require rapid absorption and have short half-lives, are ideal candidates for IR formulations because they allow for the quick establishment of therapeutic levels necessary for reliable ovulation suppression. This rapid onset of action is also essential in cases where time-sensitive contraceptive effects are needed, such as in emergency contraception. In addition to meeting pharmacodynamic requirements, IR tablets offer significant benefits in terms of patient compliance. Their typically small size and ease of swallowing, coupled with low production costs, make them an accessible and convenient option for daily use. These features enhance adherence, which is critical for the consistent efficacy of hormonal contraceptives. The stability of hormonal active pharmaceutical ingredients (APIs) in solid dosage forms further supports the use of IR tablets. These drugs generally maintain their potency and integrity over time, contributing to a longer shelf life and simpler storage requirements—an advantage for both manufacturers and end users. Moreover, IR formulations are compatible with scalable, cost-effective manufacturing processes, making them widely available in both brand-name and generic versions across global markets. From a regulatory standpoint, agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require that IR contraceptive tablets meet rigorous standards for bioequivalence and dissolution. These requirements ensure that products deliver consistent therapeutic effects and are interchangeable with reference formulations. Overall, IR tablets represent a highly practical and effective platform for delivering hormonal contraception, supported by scientific, clinical, manufacturing, and regulatory factors. Thus, IR formulations are favoured for most oral contraceptive drugs due to their effectiveness in maintaining hormonal homeostasis, predictable pharmacodynamics, and ease of patient use.

3. ADVANTAGES AND LIMITATIONS OF IMMEDIATE RELEASE FORMULATIONS

3.1 Benefits of Immediate Release Formulations

Immediate release (IR) dosage forms are the standard in oral contraceptive therapy due to their **pharmacokinetic efficiency**, **user convenience**, and **cost-effectiveness**. These formulations are designed to **disintegrate rapidly in the gastrointestinal tract**, allowing for quick absorption of the active pharmaceutical ingredients (APIs). This rapid onset of action plays a crucial role in ensuring the **effectiveness and reliability** of hormonal contraceptives.

Faster Onset of Action

One of the most prominent advantages of IR dosage forms is their **fast pharmacological onset**, which is especially beneficial in **contraceptive regimens requiring timely hormonal modulation**. After ingestion, IR tablets typically release their contents within **30 minutes**, resulting in peak plasma concentrations of hormones like ethinylestradiol and levonorgestrel within **1 to 2 hours** (19). This rapid systemic availability ensures that hormone levels are sufficient to:

Combined oral contraceptives (COCs) and progestin-only pills (POPs) prevent pregnancy through several key mechanisms: suppression of ovulation, thickening of cervical mucus, and alteration of endometrial receptivity. COCs, which contain both estrogen and progestin, suppress ovulation by inhibiting the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. This suppression prevents the maturation and release of eggs from the

ovaries. Additionally, both hormones work together to thicken cervical mucus, creating a barrier that impedes sperm penetration. The hormonal components also alter the endometrial lining, making it less receptive to a fertilized egg, thereby reducing the likelihood of implantation. POPs, which contain only progestin, primarily prevent pregnancy by thickening cervical mucus, thereby hindering sperm movement. While ovulation suppression occurs in some cycles, it is not consistent across all users. The progestin in POPs also induces changes in the endometrium, making it less suitable for embryo implantation. Furthermore, progestins can slow the movement of the ovum through the fallopian tubes, potentially reducing the likelihood of fertilization. These mechanisms collectively contribute to the efficacy of oral contraceptives in preventing pregnancy. Such prompt action is particularly critical in **start-of-cycle administration** and **emergency contraceptive situations**, where delays in hormone absorption could reduce effectiveness (20).

Improved Compliance and Convenience

IR formulations also enhance **patient adherence**, which is vital for contraceptive efficacy. These tablets are typically:

The design of oral contraceptive tablets prioritizes attributes that enhance patient adherence and ease of use. These tablets are typically small in size, facilitating easy swallowing, and are free from complicated administration techniques, making them convenient for daily use. The compact size of these tablets is intentional, as smaller tablets are generally easier to swallow. Studies have shown that tablets with a diameter of 6–8 mm are often preferred, as they are perceived as more manageable and less likely to cause discomfort during swallowing. Additionally, oval or oblong shapes are commonly used, as they are considered easier to swallow compared to round tablets. This design consideration is particularly important for populations such as the elderly, who may experience difficulty with swallowing larger or irregularly shaped tablets. Beyond size and shape, the ease of swallowing is further enhanced by the tablet's coating. Film coatings can provide a smoother surface, reducing friction and making the tablet glide more easily down the throat. This is especially beneficial for individuals who may have a sensitive gag reflex or other swallowing difficulties. The simplicity of administration is another key factor. Oral contraceptive tablets do not require any special preparation or techniques; they can be taken with water, making them convenient for daily use without the need for additional equipment or assistance. This straightforward approach supports consistent use, which is crucial for the effectiveness of the contraceptive. Their **once-daily dosing regimen**, combined with predictable onset and offset of action, makes them **user-friendly** and **suitable for long-term use**, especially in low-resource settings where healthcare follow-up may be infrequent (21). Unlike extended-release formulations that may require specialized manufacturing or variable absorption profiles, IR tablets offer a **straightforward therapeutic approach** that aligns with diverse user needs and lifestyles.

Cost-Effectiveness and Manufacturing Simplicity

Immediate release dosage forms are **inexpensive to manufacture**, making them widely accessible. Their **formulation technology** is well-established, involving conventional **wet granulation, direct compression**, or **dry granulation** methods. This contributes to the **low production cost**, which is a significant advantage in **public health programs** aimed at increasing contraceptive access (22).

Additionally, IR formulations provide **flexibility in hormonal dosing**, facilitating the development of **low-dose combinations**, **multiphasic regimens**, or **generic equivalents** without compromising therapeutic outcomes.

Rapid Reversibility

Another unique benefit of IR oral contraceptives is their **reversibility upon discontinuation**. Since the active hormones are **cleared relatively quickly** from the body, normal menstrual cycles and fertility often return within **a few weeks to months** after cessation of use (23). This makes IR contraceptives highly suitable for women planning for **short-term contraception** or transitioning between **reproductive planning stages**

3.2 Challenges of Immediate Release Formulations

While **immediate release (IR)** dosage forms are the most common and practical formulation for oral contraceptives, they are not without limitations. Challenges such as **fluctuating plasma hormone levels**, **strict dosing schedules**, and **patient adherence** concerns can impact their overall effectiveness and patient satisfaction. These drawbacks must be understood to improve formulation strategies and contraceptive outcomes.

Fluctuating Plasma Hormone Levels

One of the most significant challenges of IR contraceptive formulations is the **rapid absorption and elimination** of the active hormones. This can result in **peaks and troughs** in plasma concentrations, which may compromise consistent **endocrine suppression**, especially if doses are missed or taken irregularly (24). For example, ethinylestradiol and levonorgestrel, two commonly used hormones in COCs, reach peak plasma concentrations within 1–2 hours of ingestion and then undergo a rapid decline due to hepatic metabolism and biliary excretion (25). These fluctuations can: Low-dose oral contraceptives are formulated to minimize side effects while effectively preventing pregnancy. However, their reduced hormone levels can narrow the margin of safety for ovulation suppression, potentially increasing the risk of breakthrough ovulation. This is particularly pertinent with progestin-only pills, which require strict adherence to dosing schedules to maintain efficacy. The hormonal fluctuations associated with oral contraceptives can lead to side effects such as nausea, breast tenderness, and mood changes. These effects are often linked to the estrogen component of the pills, which can cause breast tenderness and fullness. Mood alterations may result from the influence of synthetic hormones on neurotransmitter activity in the brain, affecting serotonin and dopamine levels. It's important to note that while these side effects are common, they are generally mild and tend to subside as the body adjusts to the hormones. Nonetheless, individuals experiencing persistent or severe symptoms should consult with a healthcare provider to discuss alternative contraceptive options or adjustments to their current regimen. For those seeking contraceptive methods with potentially fewer hormonal side effects, progestin-only pills like Opill may be considered. These formulations eliminate estrogen, which may reduce the incidence of certain side effects, though they still require consistent daily intake to maintain effectiveness. Maintaining **steady-state hormone levels** is more difficult with IR formulations than with **extended-release systems**, making **daily dosing consistency** crucial for efficacy.

Strict Dosing Schedule and Compliance Issues

Another major limitation is the **requirement for strict adherence** to the daily dosing schedule. Missing a single dose—especially with **progestin-**

ISSN: 2456-4265
IJMEC 2025

only pills (POPs)—can significantly compromise contraceptive effectiveness due to the short half-life of these hormones (26). Most POPs must be taken within the same **3-hour window each day**, failing which **backup contraception** is recommended, this rigidity in dosing introduces several issues:

Adhering to a daily oral contraceptive regimen can be particularly challenging for individuals with irregular routines, leading to increased user burden. The necessity of taking the pill at the same time each day demands a level of consistency that may not align with everyone's lifestyle, especially those with unpredictable schedules. This inconsistency can result in a higher likelihood of missed pills, which is a common reason for contraceptive failure. Studies have shown that up to 47% of women do not fully adhere to their oral contraceptive regimen, with 22% missing two or more pills per cycle, thereby increasing the risk of unintended pregnancies. To mitigate these challenges, many users rely on reminder systems, such as mobile apps or text message alerts, to maintain adherence. These tools can be effective; for instance, daily text-message reminders have been shown to significantly decrease the proportion of users who experience extended gaps in pill usage. However, the effectiveness of these systems can vary, and their success often depends on the user's engagement and the personalization of the reminders. Additionally, while counseling and education about the importance of adherence are crucial, they may not always lead to improved compliance unless they are part of a comprehensive, behaviorally-informed intervention strategy. Studies have shown that real-world failure rates of oral contraceptives are significantly higher than those in clinical trials, primarily due to **poor compliance** with IR regimens (27).

First-Pass Metabolism and Drug Interactions

Immediate release contraceptives are also susceptible to **first-pass hepatic metabolism**, which can reduce **bioavailability** and alter therapeutic outcomes. This is particularly relevant in individuals taking **enzyme-inducing medications** (e.g., rifampin, phenytoin), which can increase clearance of contraceptive hormones and lower plasma levels below the threshold needed for ovulation suppression (28). Furthermore, gastrointestinal disturbances such as **vomiting or diarrhea** can reduce absorption of IR tablets, again leading to **transient reductions in hormone levels** and **risk of pregnancy**.

Lack of Hormone Reservoir Effect

IR formulations release the entire drug content quickly after ingestion, without providing a **reservoir effect** that could maintain hormone levels for extended periods. In contrast, **extended-release or long-acting delivery systems** like intrauterine devices (IUDs) or implants maintain therapeutic levels more consistently and are less susceptible to user error (29). This lack of sustained release from IR tablets makes them inherently more prone to **fluctuations and failures** if not taken precisely as directed.

4. FORMULATION STRATEGIES FOR IMMEDIATE RELEASE ORAL CONTRACEPTIVES

4.1 Choice of Excipients and Carriers

The formulation of **immediate release (IR)** oral contraceptives requires careful selection of **excipients and carriers** to ensure **rapid drug release**, **stability**, and **bioavailability**. Excipients play a critical role in the **pharmacokinetics** of the active pharmaceutical ingredients (APIs), influencing their **disintegration**, **dissolution**, and

ISSN: 2456-4265
IJMEC 2025

absorption in the gastrointestinal tract. Therefore, the excipients chosen must not only be compatible with the active drug but also help achieve **optimal therapeutic effects**.

Excipients for Immediate Release Formulations

Excipients used in IR oral contraceptives primarily serve functions such as:

In pharmaceutical formulations, excipients serve critical roles that influence the performance and efficacy of the final product. Disintegrants are incorporated to facilitate the breakup of tablets upon administration, ensuring that the active pharmaceutical ingredient (API) is released promptly for absorption. This is achieved by promoting the tablet's disintegration into smaller fragments, thereby increasing the surface area available for dissolution. Lubricants are added to formulations to reduce friction during tablet manufacturing, preventing the mixture from adhering to equipment surfaces. While they aid in the manufacturing process, certain hydrophobic lubricants, such as magnesium stearate, can impede tablet disintegration and dissolution by creating a water-repellent layer around particles. This effect can be mitigated by using hydrophilic lubricants or optimizing the concentration of hydrophobic ones. Binders are essential for imparting mechanical strength to tablets, ensuring that the compressed powder remains intact during handling and storage. They function by promoting adhesion among powder particles, forming granules that can be compressed into tablets. Common binders include starch, gelatin, and polyvinylpyrrolidone. Stabilizers are incorporated to maintain the chemical and physical integrity of the API throughout the product's shelf life. They prevent degradation pathways such as oxidation, hydrolysis, or photolysis, thereby ensuring consistent therapeutic efficacy. Examples include antioxidants and chelating agents that protect the API from reactive species. Enhancing the solubility and dissolution rate of poorly water-soluble drugs is a significant challenge in formulation development. Strategies to address this include particle size reduction, the use of surfactants, and the incorporation of solubility enhancers that improve the wettability and dispersibility of the API, facilitating its dissolution in the gastrointestinal tract. Collectively, these excipients are integral to the design of effective and reliable pharmaceutical products, ensuring optimal drug release, stability, and bioavailability.

Common excipients employed in oral contraceptive formulations include:

1. Binders

Binders are essential in maintaining the integrity of the tablet, ensuring it holds together during manufacturing and does not break apart prematurely in the gastrointestinal tract. For immediate release formulations, binders that dissolve easily and promote rapid disintegration are typically chosen. **Polyvinylpyrrolidone (PVP)**: Widely used for its excellent binding properties and ability to form clear, strong films. PVP helps tablets disintegrate rapidly in the stomach, enhancing the onset of action of oral contraceptives (30). **Cellulose derivatives (e.g., microcrystalline cellulose)**: These are commonly used as **binders** and also **disintegrants**, aiding in rapid tablet disintegration once ingested.

2. Disintegrants

Disintegrants are crucial for promoting the rapid breakdown of the tablet after administration, leading to the fast release of the active pharmaceutical ingredients. Disintegration time is particularly important in immediate release oral contraceptives to ensure **timely hormone**

absorption. **Croscaramellose sodium**: A superdisintegrant used frequently in the formulation of IR tablets, this excipient swells in the presence of water, helping the tablet to break apart and release its content efficiently (31). **Sodium starch glycolate**: Another widely used superdisintegrant, it enhances the **disintegration rate** by absorbing water and causing rapid swelling, which leads to faster dissolution and absorption of the contraceptive drug.

3. Fillers and Diluents

Fillers are added to **bulk up the tablet** when the active drug is present in small amounts. They ensure the **proper tablet size** for easy swallowing and improve the overall **mechanical properties** of the dosage form.

Lactose: One of the most commonly used fillers, it is compatible with a wide range of active pharmaceutical ingredients and helps in achieving the desired tablet weight and volume (32).

Mannitol: Often used in chewable tablets, mannitol provides the necessary **tablet bulk** and also contributes to **pleasant mouthfeel**, which can improve patient compliance.

4. Solubilizing Agents

For poorly soluble active ingredients, solubilizers are used to **enhance drug dissolution**. This is especially important for oral contraceptives that may have low **water solubility**.

Cyclodextrins: These compounds form inclusion complexes with poorly soluble drugs, improving their solubility and dissolution rate. Cyclodextrins are commonly used to enhance the bioavailability of oral contraceptives (33).

Polysorbates: These surfactants help in solubilizing hydrophobic drugs, aiding in their absorption through the gastrointestinal tract.

5. Lubricants

Lubricants are incorporated into the formulation to **prevent sticking** to the punch and die during tablet compression, ensuring **smooth manufacturing** and enhancing **tablet release properties**. Common lubricants include:

Magnesium stearate: A widely used lubricant that ensures smooth tablet compression and aids in the tablet's **easy release** from the molds (34).

Stearic acid: Another lubricant used in combination with magnesium stearate to ensure optimal tablet formation.

Choice of Carriers

In addition to excipients, the choice of carriers in oral contraceptive formulations also plays an essential role in the **release profile** and **stability** of the drug. Carriers are substances that aid in delivering the API to the site of absorption and can modify the dissolution characteristics of the drug.

1. Polymers

Polymers such as **hydroxypropylmethylcellulose (HPMC)** are sometimes used in immediate release formulations due to their ability to enhance **tablet disintegration** while controlling the release rate of poorly soluble drugs (35). These polymers help in achieving consistent and predictable **drug release profiles**.

2. Soluble Supports

Materials like **gelatin** can be used as carriers for certain oral contraceptives to **improve dissolution** and **bioavailability**. Gelatin is a water-soluble polymer that can **enhance solubility** and **increase the rate of absorption** of poorly soluble drugs, thereby improving their overall effectiveness.

4.2 Direct Compression and Granulation Techniques

The manufacturing process of **immediate release (IR)** oral contraceptives significantly influences

ISSN: 2456-4265
IJMEC 2025

their **quality**, **bioavailability**, and **patient compliance**. Among various formulation strategies, **direct compression** and **granulation techniques** are two of the most common approaches used in the production of oral contraceptive tablets. These methods ensure the desired **drug release profile**, **tablet integrity**, and **uniformity** in dosage. This section elaborates on both techniques and their relevance to IR oral contraceptive formulations.

Direct Compression

Direct compression is a widely adopted technique in the pharmaceutical industry for the production of tablets. This method involves the compaction of powder blends directly into tablets without the need for prior wetting or drying, making it a **cost-effective and time-efficient** process. Direct compression is particularly advantageous in the formulation of immediate release oral contraceptives due to its simplicity and ability to maintain the **physical stability** of sensitive active pharmaceutical ingredients (APIs).

Advantages of Direct Compression

Simplicity and Cost-Effectiveness: Direct compression does not require the use of solvents, binders, or significant amounts of processing equipment. This makes the technique cost-effective, reducing overall manufacturing costs for **oral contraceptive tablets** (36).

Preservation of API Stability: Since no heat or solvents are involved, direct compression is ideal for APIs that are sensitive to **moisture**, **temperature**, or **chemical degradation**. This is particularly important for **hormonal drugs** used in oral contraceptives, which need to remain stable during manufacturing and storage (37).

Faster Production Time: The direct compression process is generally faster compared to traditional wet granulation methods, which involves multiple steps like drying and screening. This results in a quicker turnaround time for the production of oral contraceptive tablets (38).

Challenges and Considerations in Direct Compression

Need for Suitable Excipients: The formulation must include excipients that can **flow well**, **compress uniformly**, and ensure tablet cohesion without the need for additional binders or granulation steps. Common excipients used in direct compression include **microcrystalline cellulose**, **lactose**, and **starch-based** excipients (39).

Limited to Certain Drug Properties: Not all drugs are suitable for direct compression due to their **poor flow properties**, **inconsistent particle size**, or **low compressibility**. In such cases, granulation techniques may be preferred.

Granulation Techniques

Granulation involves the aggregation of primary powder particles to form granules, which are then compressed into tablets. There are two primary types of granulation techniques used in the manufacturing of IR oral contraceptives: **wet granulation** and **dry granulation**. Granulation techniques are particularly useful when the drug has poor flow properties or requires a controlled particle size distribution for uniformity.

Wet Granulation

In **wet granulation**, a liquid binder is added to the powder blend to form a damp mass. This mass is then passed through a screen to form granules, which are dried and blended with additional excipients before compression into tablets. Wet granulation is commonly employed for oral contraceptives when APIs require **improved flowability**, **better compression**, and **consistent dissolution** profiles.

Advantages of Wet Granulation

Enhanced Uniformity: Wet granulation helps in achieving **uniform distribution** of active pharmaceutical ingredients (APIs), improving **dose uniformity** in each tablet (40).

Improved Flow and Compressibility: The granulation process improves the **flowability** and **compressibility** of the powder blend, which can be beneficial for drugs that are not ideal for direct compression due to their **poor powder properties**.

Challenges of Wet Granulation

Time and Resource Intensive: The wet granulation process requires several stages such as **wet mixing**, **drying**, and **screening**, which increase manufacturing time and costs (41).

Stability Concerns: The use of heat and moisture during the wet granulation process can lead to the **degradation** or **instability** of certain drugs, particularly **sensitive APIs** used in oral contraceptives.

Dry Granulation

In **dry granulation**, the powder blend is compacted under high pressure to form granules without the use of a binder or liquid. This method is used when the API is **sensitive to heat or moisture** and cannot withstand the conditions of wet granulation.

Advantages of Dry Granulation

No Use of Solvents or Heat: Dry granulation eliminates the need for **heat** or **moisture**, making it suitable for heat-sensitive APIs. This is particularly relevant for oral contraceptives containing **hormonal drugs**, which are sensitive to temperature and humidity (42).

Reduced Process Time: Dry granulation involves fewer steps compared to wet granulation, offering a quicker manufacturing timeline.

Challenges of Dry Granulation

Limited to Certain Formulations: Dry granulation is not suitable for all drug formulations, especially those that require high binding or cohesive properties. In some cases, it may lead to **poor granule formation**, which can affect tablet quality.

Less Control Over Granule Size: Dry granulation may result in a broader particle size distribution compared to wet granulation, which could affect the **uniformity of the drug release** (43).

Applications in Immediate Release Oral Contraceptives

Both direct compression and granulation techniques are applicable to **immediate release oral contraceptives** depending on the formulation requirements.

Direct compression is more suitable for simple formulations where the active ingredient has **good flow properties** and **compressibility**. Many **progestin-only** and **combined oral contraceptives** with relatively **stable active ingredients** can be manufactured using direct compression (44).

Granulation is more beneficial when there is a need to modify the dissolution rate, improve **uniformity**, or address **poor flow properties** of the drug. Granulation can also be used for oral contraceptive tablets that require **controlled release** or those containing **complex active ingredients** that need **more advanced formulation techniques** (45).

4.3 Use of Superdisintegrants

Superdisintegrants are essential excipients in the formulation of immediate release (IR) dosage forms, including **oral contraceptive tablets**, as they play a crucial role in ensuring rapid disintegration and dissolution. **Superdisintegrants** are substances added to the tablet formulation to enhance the **breakup** of the tablet when it comes into contact with the aqueous environment of the gastrointestinal tract. Their primary function is to ensure that the tablet disintegrates quickly and the

active pharmaceutical ingredient (API) is released rapidly, which is crucial for achieving the desired **bioavailability** and therapeutic effect in oral contraceptives.This section explores the **importance** of superdisintegrants in the development of **IR oral contraceptive formulations**, including their mechanisms of action, types, and the criteria for their selection.

Role of Superdisintegrants in Immediate Release Formulations

The success of **IR oral contraceptives** largely depends on the rapid and complete release of the active pharmaceutical ingredients (APIs) once the tablet is ingested. In conventional tablets, disintegration can be a slow process due to the **hydrophobic nature** of some excipients or the dense formulation. To address this, superdisintegrants are used to promote rapid **disintegration** in the stomach, thus facilitating the **dissolution** and **absorption** of the drug. This is particularly important for oral contraceptives, where **consistent plasma drug levels** are essential for effectiveness. Superdisintegrants work by enhancing the **water uptake** or swelling of the tablet upon contact with gastric fluids. The swelling force causes the tablet to break into smaller fragments, which increases the surface area and promotes faster dissolution of the drug.

Types of Superdisintegrants

Several classes of **superdisintegrants** are commonly used in the formulation of **IR oral contraceptives**. These include:

1. **Cross-linked Celluloses**:

   Croscarmellose sodium is one of the most commonly used superdisintegrants. It is highly effective due to its ability to rapidly swell when exposed to water, leading to the breakdown of the tablet structure. It works by absorbing water and forming a gel-like mass that facilitates disintegration (46). **Crosslinked carboxymethyl cellulose** (e.g., **Ac-Di-Sol**) is also used for its excellent disintegration properties. It enhances the break-up of tablets by absorbing water, causing a significant increase in the volume and helping the drug dissolve quickly.

   Cross-linked Starches:

   Sodium starch glycolate (SSG) is another popular superdisintegrant used in tablet formulations. It swells upon water contact and promotes disintegration, thereby increasing the drug's dissolution rate. SSG is widely used in **progestin-only** and **combined oral contraceptives** due to its **low cost** and **effectiveness** (47). **Pregelatinized starch** is also used as a superdisintegrant. This modified starch helps tablets to disintegrate in a controlled manner, which can be particularly beneficial in oral contraceptive formulations that require rapid onset.

2. **Clay-Based Disintegrants**:

   Kieselguhr and **Magnesium trisilicate** are examples of disintegrants derived from clay. These disintegrants promote the breakup of tablets by absorbing water and facilitating the dispersion of the drug (48).

3. **Synthetic Polymers**:

   Polyvinyl alcohol and **polyvinyl pyrrolidone** are examples of synthetic polymers that function as superdisintegrants. These materials swell upon hydration and can enhance the disintegration of tablets, contributing to **faster drug release**.

Mechanism of Action of Superdisintegrants

The primary mechanisms through which superdisintegrants act to promote tablet disintegration include:

Swelling: Superdisintegrants absorb water when exposed to gastric fluids, causing them to swell. The increased volume leads to a forceful break-up of the

tablet. This mechanism is essential for the **rapid onset of action** in oral contraceptives.

Capillary Action: Some superdisintegrants, particularly **cross-linked celluloses**, enhance water penetration into the tablet matrix via capillary forces. This water absorption leads to rapid swelling and the breakdown of the tablet structure (49).

1. **Particle Size and Surface Area**: The ability of superdisintegrants to reduce the tablet size through swelling and fragmentation results in a large **surface area** for drug dissolution, contributing to faster **drug release** and more efficient absorption in the gastrointestinal tract.
2. **Erosion**: Certain superdisintegrants contribute to tablet disintegration by eroding the tablet matrix, thereby aiding in the faster release of the active ingredient (50).

Selection Criteria for Superdisintegrants

The choice of superdisintegrant for a specific oral contraceptive formulation depends on several factors, including:

When selecting a superdisintegrant for oral contraceptive formulations, several key factors must be considered to ensure optimal performance and safety. The chosen superdisintegrant should demonstrate efficiency in disintegration by promoting rapid and complete tablet breakup in the gastrointestinal tract, thereby allowing the active pharmaceutical ingredient (API) to become promptly available for absorption. Additionally, chemical compatibility with the API is crucial; the superdisintegrant must not interact adversely with the active ingredients or compromise their stability, which is particularly important for sensitive formulations like oral contraceptives. Safety is a fundamental requirement, meaning the superdisintegrant must comply with regulatory standards established by authorities such as the FDA and EMA. It should be non-toxic, biologically inert, and approved for use in oral pharmaceutical products to protect patients while maintaining product integrity. Cost-effectiveness is also a critical consideration, especially for large-scale production of widely used medications like oral contraceptives. Utilizing a cost-efficient superdisintegrant can help maintain affordability without sacrificing quality. Finally, ease of handling plays an important role in manufacturing. The superdisintegrant should be easily incorporated into the formulation and must not introduce processing difficulties during tablet production. Ensuring smooth manufacturing processes helps maintain consistent quality and efficiency in producing oral contraceptive tablets while adhering to the necessary regulatory and safety standards.

Advantages of Using Superdisintegrants in IR Oral Contraceptives

1. **Faster Onset of Action**: By promoting rapid disintegration, superdisintegrants help achieve quicker drug release, leading to faster therapeutic effects. This is particularly important for oral contraceptives, where **immediate bioavailability** is necessary for effectiveness (52).
2. **Improved Compliance**: Tablets that disintegrate quickly are more likely to meet patient expectations for convenience and ease of use, potentially improving **patient compliance** with contraceptive regimens.
3. **Consistency and Reliability**: Superdisintegrants contribute to **batch-to-batch consistency** in tablet disintegration, which ensures uniform **drug absorption** and enhances the reliability of the therapeutic effects of oral contraceptives.

Challenges and Limitations of Superdisintegrants

1. **Overuse and Impact on Tablet Hardness**: While superdisintegrants are essential for disintegration,

overuse may compromise the **mechanical strength** of the tablet, leading to issues such as **fragility** or **difficulty in handling** (53).

2. **Potential for Inconsistent Disintegration**: In some cases, superdisintegrants may not perform consistently across different batches or formulations, leading to variations in the onset of drug release (54).
3. **Limited Knowledge of Long-Term Effects**: While superdisintegrants are generally regarded as safe, their **long-term effects** when used in combination with other excipients and active ingredients in oral contraceptives are not always well understood. Further studies are needed to assess any **potential interactions**.

4.4 Role of Solubility and Permeability Enhancement Techniques

The **bioavailability** of oral contraceptive drugs is significantly influenced by their **solubility** and **permeability**. For oral contraceptives to be effective, they must rapidly dissolve in the gastrointestinal tract and cross the intestinal membranes to reach systemic circulation. This section explores the role of **solubility** and **permeability enhancement techniques** in the formulation of **immediate release (IR) oral contraceptive drugs**, focusing on their importance in ensuring **rapid drug absorption** and **therapeutic efficacy**.

Solubility Enhancement Techniques

Many active pharmaceutical ingredients (APIs) in oral contraceptives suffer from **poor water solubility**, which can limit their absorption and reduce bioavailability. The **solubility** of the drug directly impacts the rate of dissolution and, consequently, the **onset of action**. To address this challenge, various formulation strategies can be employed to **enhance the solubility** of poorly soluble drugs, ensuring that the **API** is readily available for absorption in the gastrointestinal tract.

1. Solid Dispersions

Solid dispersions are a widely used technique for enhancing the solubility of poorly soluble drugs. In this approach, the drug is dispersed in a carrier matrix, which improves its wettability and dissolution rate. **Polymeric carriers** like **polyvinylpyrrolidone (PVP)** and **hydroxypropyl methylcellulose (HPMC)** are commonly used for this purpose. Solid dispersions are beneficial for **oral contraceptives**, as they improve the **bioavailability** of APIs that are otherwise poorly soluble in water (55). **Example**: **Ethinyl estradiol**, an active ingredient in combined oral contraceptives, has been shown to have enhanced solubility when formulated as a solid dispersion with **PVP** (56).

2. Salt Formation

The formation of salts is another common technique to enhance the solubility of drugs. **Weakly acidic drugs** can form salts with **alkaline agents** to increase solubility. This technique is particularly useful for drugs with poor solubility in their neutral form but enhanced solubility when in salt form. In oral contraceptives, salts like **ethinyl estradiol sodium** can be utilized to increase solubility and **dissolution rate** (57).

3. Nanocrystals and Nanoparticles

Nanotechnology offers a promising approach for improving the solubility of poorly soluble drugs. **Nanocrystals** or **nanoparticles** of the API can be formulated, increasing the **surface area** and improving the rate of dissolution. **Nanocrystal technology** has been shown to be effective for enhancing the **bioavailability** of lipophilic drugs in oral contraceptives, as the increased surface area promotes faster **drug dissolution** (58).

4. Cyclodextrins

Cyclodextrins are cyclic oligosaccharides that can form inclusion complexes with poorly soluble drugs, enhancing their solubility. By encapsulating the drug within the hydrophobic cavity of the cyclodextrin, the **solubility** of the drug in aqueous media is improved. This technique has been applied in oral contraceptive formulations to enhance the solubility of **progesterone** and **ethinyl estradiol** (59).

Permeability Enhancement Techniques

Once a drug is dissolved in the gastrointestinal tract, it must then pass through the intestinal membrane to enter the systemic circulation. However, many drugs, particularly those with low **intestinal permeability**, face challenges in crossing the **intestinal epithelial cells**. Therefore, enhancing the **permeability** of oral contraceptives is crucial for ensuring adequate absorption and therapeutic efficacy.

1. Use of Permeation Enhancers

Permeation enhancers, or **absorption enhancers**, are substances that temporarily increase the permeability of the gastrointestinal tract to facilitate drug absorption. These enhancers work by altering the **tight junctions** between intestinal cells or by increasing the fluidity of the cell membranes. Common **permeation enhancers** used in the formulation of oral contraceptives include:

Chitosan: This biopolymer has been shown to enhance the permeability of lipophilic drugs by interacting with the intestinal mucosa and increasing drug transport (60).

Fatty acids and surfactants: Certain **fatty acids** (e.g., **caprylic acid**) and **surfactants** (e.g., **polysorbate 80**) are known to enhance drug absorption by disrupting the lipid bilayer of the intestinal membrane, allowing for better drug permeation (61).

2. Lipid-Based Formulations

Lipid-based formulations, such as **self-emulsifying drug delivery systems (SEDDS)**, are an effective approach for improving the **intestinal permeability** of oral contraceptives. These formulations include lipid excipients that form **microemulsions** when in contact with water, which can enhance drug solubilization and increase permeability through the intestinal membranes. **Lipid-based delivery systems** have been used to improve the absorption of **hydrophobic drugs** in oral contraceptives (62).

3. Prodrug Approaches

Prodrugs are chemically modified versions of the active drug that are designed to enhance **intestinal permeability**. After absorption, the prodrug is converted into the active form by enzymatic cleavage within the body. Prodrug strategies are effective for oral contraceptives because they can increase **permeability** and **bioavailability** while also potentially offering controlled-release benefits (63). **Ethinyl estradiol** prodrugs, for example, have been studied to improve **intestinal permeability** and provide sustained drug action.

4. Microneedle Technology

Though still in its early stages for oral formulations, **microneedle technology** offers a novel approach to increasing drug permeability. **Microneedles**, which are usually employed in transdermal drug delivery, can also be designed to penetrate the **intestinal mucosa**, facilitating the absorption of poorly permeable drugs. This technology could revolutionize **oral contraceptive** delivery in the future by enhancing absorption through the intestinal wall (64).

Synergy between Solubility and Permeability Enhancements

Both **solubility** and **permeability** are critical for the effective absorption of oral contraceptives. While

solubility determines how quickly the drug dissolves in the gastrointestinal tract, **permeability** dictates how efficiently the dissolved drug crosses the intestinal barrier. Therefore, employing both solubility and permeability enhancement strategies in tandem is often necessary for the formulation of highly effective **immediate release oral contraceptive tablets**.

For instance, using a combination of **nanocrystals** to enhance solubility and **lipid-based formulations** to increase permeability may offer synergistic benefits, ensuring that the **active ingredient** in the contraceptive is rapidly dissolved and effectively absorbed by the body.

5. PHARMACOKINETIC CONSIDERATIONS

5.1 Absorption Profile of Oral Contraceptives

The **absorption profile** of oral contraceptives plays a crucial role in determining their **effectiveness**, **onset of action**, and **overall therapeutic efficacy**. Pharmacokinetic properties, including **absorption**, **distribution**, **metabolism**, and **excretion**, are essential considerations when formulating oral contraceptives to ensure they meet the clinical requirements of both efficacy and safety. In this section, we will specifically focus on the **absorption profile** of **immediate release (IR) oral contraceptive formulations**.

Absorption Mechanism and Site

The primary goal of any oral contraceptive is to ensure that the **active pharmaceutical ingredient (API)** is absorbed efficiently into the bloodstream to exert its desired effects. Upon oral administration, oral contraceptives undergo **absorption** through the gastrointestinal tract, primarily in the **small intestine**, due to its **large surface area**, and the **presence of enzymes and transporters** that facilitate drug absorption.

Drug Dissolution: The first step in absorption is the dissolution of the oral contraceptive tablet. In the case of **immediate-release (IR) formulations**, the drug must dissolve quickly and efficiently in the stomach or upper gastrointestinal tract to ensure rapid absorption. Dissolution depends on various factors such as **solubility**, **particle size**, and **pH** of the drug. Drugs with **low solubility** or **poor dissolution rates** may experience delays in absorption and result in **suboptimal bioavailability** (65).

Absorption in the Small Intestine: Once the drug dissolves, the **active ingredient** is absorbed through the **intestinal wall** into the systemic circulation. **Lipophilic drugs**, such as **ethinyl estradiol**, typically follow a **passive diffusion** mechanism across the epithelial cells lining the small intestine. These drugs must cross the **intestinal epithelial cells**, which are selectively permeable, to enter the bloodstream (66).

Transporters: Many drugs, including oral contraceptives, utilize **active transport mechanisms** involving **solute carriers** and **ATP-binding cassette (ABC) transporters** such as **P-glycoprotein** to enhance absorption (67). In some cases, certain excipients are included in the formulation to facilitate the absorption of poorly soluble or poorly permeable drugs by affecting the transporters in the intestine (68).

First-Pass Metabolism: After absorption, oral contraceptive drugs often undergo **first-pass metabolism** in the **liver**. This phase is essential because it impacts the **bioavailability** of the active drug. For oral contraceptives, especially those containing **estrogen** and **progestin**, the liver metabolizes the active ingredients before they reach systemic circulation. This metabolic process significantly reduces the concentration of active

drug that reaches the systemic circulation and can influence the **overall therapeutic effect** (69).

Ethinyl Estradiol: As a highly lipophilic molecule, **ethinyl estradiol**, the estrogen component of combined oral contraceptives, undergoes significant **first-pass metabolism** in the liver, leading to a reduction in its bioavailability. To compensate for this, the dosage is carefully adjusted to ensure that enough of the active drug reaches the systemic circulation (70).

Factors Affecting Absorption

The **absorption profile** of oral contraceptives can be affected by several factors that may vary from patient to patient. These factors must be considered when designing **immediate-release (IR) formulations** to optimize their **efficacy** and **safety**.

1. **Formulation Factors**:

Excipients: The choice of excipients and their concentration can impact the dissolution rate and the absorption profile. **Superdisintegrants**, such as **crosslinked polyvinylpyrrolidone (PVP)**, can improve the **disintegration** of the tablet, leading to faster **dissolution** and **faster absorption** (71). The use of **solubilizing agents** like **polysorbate 80** can also enhance drug solubility and absorption, particularly for lipophilic drugs (72).

Particle Size: The **particle size** of the active pharmaceutical ingredient can influence the rate of absorption. Smaller particles have a higher surface area, allowing for **faster dissolution** and more efficient absorption (73).

2. **Gastrointestinal Factors**:

Gastric pH: The pH of the stomach can affect the solubility of the active drug. For example, drugs that are **weakly acidic** may have enhanced solubility in a more acidic environment (74). **Gastric pH variations**, such as those caused by food intake or conditions like **gastritis**, can alter the dissolution and absorption rates of oral contraceptives.

Gastric Emptying Time: The rate at which the stomach empties can also influence the absorption of oral contraceptives. A **faster gastric emptying** leads to quicker delivery of the drug to the **small intestine**, potentially accelerating absorption (75).

3. **Patient-Specific Factors**:

Age: The **age** of the patient can affect the **absorption** of oral contraceptives. **Elderly patients** or those with compromised gastrointestinal function may experience slower gastric emptying and altered **intestinal permeability**, affecting the overall absorption profile (76).

Body Weight and Composition: **Body mass index (BMI)** and **body fat composition** can influence the absorption of **lipophilic drugs**, such as the **ethinyl estradiol** in combined oral contraceptives. Higher body fat can impact the distribution and absorption of such drugs (77).

Presence of Food: Food can significantly influence the absorption of oral contraceptives. Some drugs may exhibit **increased absorption** when taken with food, while others may have **reduced bioavailability** due to interference with the dissolution process (78).

Clinical Implications of Absorption Profile

The **absorption profile** of immediate-release oral contraceptives has significant clinical implications. **Delayed absorption** or **inconsistent bioavailability** can compromise contraceptive effectiveness. If the active drug is not absorbed in a timely manner, or if its plasma concentration falls below the **therapeutic threshold**, contraceptive efficacy can be compromised, leading to **breakthrough bleeding** or **unintended pregnancies**.

To mitigate such risks, formulation strategies focus on ensuring rapid dissolution and consistent absorption. This is particularly important for

ISSN: 2456-4265
IJMEC 2025

combined oral contraceptives containing **ethinyl estradiol** and **levonorgestrel** or other progestins, as fluctuations in their plasma concentrations could impact **cycle control** and **pregnancy prevention** (79).

5.2 Bioavailability and First-Pass Metabolism

Bioavailability and first-pass metabolism are two key pharmacokinetic properties that critically influence the **effectiveness** and **clinical outcomes** of oral contraceptives. Understanding these factors is essential when developing immediate-release (IR) formulations for **oral contraceptives**, as they directly affect the **systemic exposure** of the drug, its **therapeutic efficacy**, and the overall **patient compliance**.

Bioavailability of Oral Contraceptives

Bioavailability refers to the fraction of the administered drug that reaches the **systemic circulation** in its active form and is available to exert a pharmacological effect. The bioavailability of oral contraceptives is largely influenced by several factors including **absorption**, **first-pass metabolism**, and the **solubility** of the active pharmaceutical ingredients (APIs).

1. **Solubility and Dissolution**: Oral contraceptives typically contain **ethinyl estradiol** (an estrogen) and a **progestin**. These compounds must dissolve quickly in the **gastrointestinal (GI) tract** to ensure efficient absorption. However, drugs with **low solubility**, such as **ethinyl estradiol**, may have **poor bioavailability**, as they require a large quantity of dissolved drug to cross the **intestinal membrane**. Consequently, solubility-enhancing technologies are often employed in the formulation to ensure sufficient drug absorption and optimal bioavailability (80).
2. **Food-Drug Interactions**: The bioavailability of oral contraceptives can be affected by the presence of food in the stomach. In some cases, food may enhance absorption by increasing gastric **pH** and promoting drug dissolution, while in other cases, food may reduce bioavailability by forming **complexes** with the drug or affecting **gastric emptying time**. Therefore, bioavailability studies are critical in determining the optimal conditions for drug administration (81).
3. **Interpatient Variability**: Bioavailability can also vary between individuals due to factors such as **age**, **body weight**, **genetic differences**, and underlying **gastrointestinal conditions**. For instance, some individuals may have variations in **P-glycoprotein** transporters, which can impact the absorption of oral contraceptives. This variability underscores the importance of understanding the **patient population** when designing immediate-release formulations (82).

First-Pass Metabolism

First-pass metabolism, also known as **presystemic metabolism**, occurs primarily in the **liver** and significantly affects the **bioavailability** of drugs taken orally. After absorption from the gastrointestinal tract, the drug enters the **portal circulation** and is transported directly to the liver, where it undergoes enzymatic transformation by the **cytochrome P450 enzymes**. This process can reduce the amount of active drug that enters the **systemic circulation**, thereby impacting its **therapeutic action**.

Metabolism of Ethinyl Estradiol: One of the most significant examples of first-pass metabolism in oral contraceptives is the metabolism of **ethinyl estradiol**, the **estrogen component** in many combined oral contraceptives (COCs). Ethinyl estradiol is extensively metabolized in the liver by enzymes such as **CYP3A4** and **CYP1A2** before it reaches the systemic circulation. As a result, the **bioavailability** of **ethinyl estradiol** can be as low

as **40-60%** (83). This first-pass effect necessitates the use of a higher dose of **ethinyl estradiol** in oral contraceptives to ensure adequate systemic exposure to the estrogen component.

Progestin Metabolism: Similarly, **progestins** such as **levonorgestrel** also undergo **first-pass metabolism** in the liver, though their metabolism is typically less extensive compared to **ethinyl estradiol**. The metabolism of **progestins** involves enzymes like **CYP3A4**, but their impact on the overall bioavailability of the active drug may be less pronounced (84). However, variations in the metabolism of progestins can affect both **pregnancy prevention** and **cycle control**, making **bioavailability** an important parameter in formulation design.

Impact of First-Pass Metabolism on Dosing: The first-pass effect is a key reason why oral contraceptive formulations are designed with specific doses of **ethinyl estradiol** and **progestins** to overcome the **bioavailability reduction** that occurs due to liver metabolism. In some cases, pharmaceutical strategies such as **extended-release formulations** or **altering the excipient composition** (e.g., use of **solubilizing agents** or **lipid-based systems**) are employed to optimize the **bioavailability** of oral contraceptives and ensure that sufficient amounts of the active ingredients are absorbed and available to exert their contraceptive effects (85).

Factors Affecting First-Pass Metabolism

The extent of **first-pass metabolism** and the subsequent **bioavailability** of oral contraceptives can be influenced by several factors, which include:

1. **Enzyme Activity**: The activity of **cytochrome P450 enzymes** can vary between individuals, impacting the rate of **first-pass metabolism**. Enzyme induction (e.g., by drugs like **rifampin**) can increase the metabolism of oral contraceptives, while enzyme inhibition (e.g., by **grapefruit juice**) can decrease metabolism, leading to higher systemic exposure and potentially increasing the risk of **adverse effects** (86).
2. **Liver Function**: Individuals with **liver dysfunction** (such as those with **hepatitis** or **cirrhosis**) may have impaired **first-pass metabolism**, which can result in **higher bioavailability** of oral contraceptives. This may increase the risk of side effects, and careful dose adjustments may be required in such cases (87).
3. **Drug Interactions**: The use of other medications can also influence the **first-pass metabolism** of oral contraceptives. For example, **anticonvulsants** and **antibiotics** may induce liver enzymes, potentially lowering the effectiveness of oral contraceptives. Conversely, certain **antifungals** and **antiretroviral agents** may inhibit metabolism, leading to higher systemic concentrations of the drug (88).
4. **Gender and Age**: Gender and age also play roles in the metabolism of drugs. Women may metabolize drugs differently than men, and older adults often experience a decline in **hepatic function**, which could affect the **first-pass effect** and alter **bioavailability** (89).

Clinical Implications

Understanding **bioavailability** and **first-pass metabolism** is essential for optimizing the **efficacy** of oral contraceptives. These pharmacokinetic factors highlight the importance of designing **immediate-release formulations** that ensure the drug's effective absorption and bioavailability while accounting for the inevitable **first-pass metabolism** that reduces systemic concentrations of the active ingredients. Such formulations must aim to balance effective dosing with the potential for **side effects**, ensuring both **contraceptive efficacy** and **safety**.

5.3 Impact of Food and Gastrointestinal pH

The **absorption** of oral contraceptive drugs can be significantly influenced by various physiological factors, including the **presence of food** and the **pH of the gastrointestinal (GI) tract**. These factors are important considerations for the development and efficacy of **immediate-release (IR) dosage forms** of oral contraceptives. Understanding how food and GI pH affect the **pharmacokinetics** of oral contraceptives allows for improved **formulation design** and more effective patient guidance on drug administration.

Impact of Food on the Absorption of Oral Contraceptives

Food intake can affect the **dissolution**, **absorption**, and **bioavailability** of oral contraceptive drugs. While some oral contraceptives may require specific administration instructions (such as with or without food), the overall impact of food varies based on the **drug formulation**, the **type of food**, and **individual patient factors** (90).

1. **Food as a Positive Modulator of Absorption**: For some oral contraceptives, particularly those with **poor solubility**, taking the drug with food can enhance its dissolution. Food increases the **gastric pH**, which may facilitate the dissolution of poorly soluble compounds. It also slows **gastric emptying**, leading to a prolonged residence time in the stomach, potentially improving drug absorption (91). For example, certain formulations of **ethinyl estradiol** in **combined oral contraceptives** (COCs) may benefit from food intake, which enhances the drug's solubility and absorption (92).
2. **Food-Induced Interactions and Reduced Absorption**: On the other hand, some foods can negatively influence the absorption of oral contraceptives. **High-fat meals** can alter the solubility and bioavailability of some active ingredients, either by forming **insoluble complexes** or by affecting the **rate of gastric emptying** (93). For instance, studies have shown that **grapefruit juice**, which inhibits the **CYP3A4 enzyme**, may increase the plasma concentration of some progestins and **ethinyl estradiol**, while **antacids** and certain foods that increase **gastric pH** can interfere with the absorption of some drug components (94).
3. **Variable Food Effects Across Different Drugs**: The effect of food on oral contraceptives is not uniform across all drugs or formulations. **Progestins**, for example, may have a different **absorption profile** when taken with food, compared to **estrogens** like **ethinyl estradiol**. Consequently, clinical guidelines often specify whether oral contraceptives should be taken with food, based on the drug's pharmacokinetic properties (95).

Impact of Gastrointestinal pH on Oral Contraceptives

The **pH** of the **gastrointestinal tract** plays a significant role in the solubility and absorption of oral contraceptive drugs. The **gastric pH** is highly variable and can fluctuate based on **fasting** versus **fed states**, the presence of **acid-reducing medications**, and **individual differences** in **gastric acid secretion**. This variability can influence the **bioavailability** of oral contraceptives.

1. **Influence of Gastric pH on Drug Solubility**: Many drugs, including oral contraceptives, have **poor solubility** at low pH (in the acidic environment of the stomach). When the **gastric pH** is raised—either due to food intake or through the use of **proton pump inhibitors (PPIs)** or **antacids**—the solubility of these drugs may increase, leading to enhanced **drug absorption**. This effect is particularly relevant for oral contraceptives containing **ethinyl estradiol**, a

compound known to be poorly soluble in highly acidic environments (96).

2. **Proton Pump Inhibitors (PPIs)**: The use of **PPIs** or **H2 receptor antagonists** can significantly alter gastric pH, raising it from a normally acidic level of 1.5-3.5 to a higher, more alkaline range (97). This alteration in pH can potentially affect the solubility and absorption of oral contraceptive drugs. For example, a higher gastric pH may reduce the solubility of **ethinyl estradiol** and other **progestins**, potentially reducing their bioavailability and effectiveness. This underscores the need for careful consideration when prescribing oral contraceptives to individuals on **acid-reducing therapies** (98).
3. **Gastrointestinal pH and Drug Absorption in Immediate-Release Formulations**: In **immediate-release formulations**, where the drug is designed to be rapidly dissolved and absorbed in the stomach or upper gastrointestinal tract, changes in gastric pH can result in **variability** in the rate and extent of absorption. **Ethinyl estradiol**, for instance, may experience **reduced bioavailability** when the gastric pH is raised in the presence of food or antacid use, which could impact the effectiveness of the contraceptive (99).
4. **Individual Variability in GI pH**: Individual variations in **gastric acid secretion** and **intestinal transit time** further contribute to the variability in drug absorption. Some individuals naturally have a **higher gastric pH**, which may necessitate dose adjustments in oral contraceptive formulations. This is particularly important for **progestin-only pills (POPs)** or formulations where consistent bioavailability is crucial for contraceptive effectiveness (100).

6. EVALUATION PARAMETERS OF IMMEDIATE RELEASE DOSAGE FORMS

6.1 Preformulation Studies

Preformulation studies are an essential early phase in the development of **immediate release (IR) dosage forms** for **oral contraceptive drugs**. These studies help to characterize the physicochemical properties of the **active pharmaceutical ingredients (APIs)** and **excipients**, allowing formulators to design the dosage form that ensures optimal **bioavailability** and **efficacy**. Preformulation studies are critical in understanding how different **formulation variables**, including excipients, processing methods, and environmental conditions, can impact the final product's quality and performance. The goal of preformulation is to determine the appropriate selection and combination of excipients, establish the stability profile, and predict the drug's **dissolution behavior**.

Key Aspects of Preformulation Studies in Oral Contraceptive Dosage Forms

1. Physicochemical Properties of the Active Pharmaceutical Ingredient (API)

The physicochemical properties of the **API** in oral contraceptives directly influence the selection of excipients, the method of manufacture, and the **release profile** of the dosage form. These properties include:

Solubility: The solubility of the active drug in water is one of the most critical properties for **immediate-release formulations**. Drugs with poor aqueous solubility may exhibit reduced bioavailability and delayed onset of action, which can affect contraceptive efficacy. For example, **ethinyl estradiol** (a common active ingredient in combined oral contraceptives) has limited solubility in water, and formulation strategies are employed to enhance its solubility and subsequent absorption (101).

ISSN: 2456-4265
IJMEC 2025

Stability: The **chemical stability** of the API under different storage conditions is paramount. Preformulation studies determine how the API degrades over time and whether it requires specific conditions (such as refrigeration or protection from light) to maintain its potency. For oral contraceptives, stability testing may also include evaluating the stability of the formulation in **solid dosage forms** (e.g., tablets) under various environmental conditions like temperature, humidity, and exposure to light (102).

Melting Point and Polymorphism: The **melting point** and **polymorphic forms** of the API affect its solubility and dissolution rate. **Polymorphs** (different crystalline forms) can have varying dissolution characteristics, which may impact the **onset** and **duration of contraceptive action**. Identifying the most suitable polymorph for formulation is part of the preformulation studies (103).

2. Selection of Excipients

Choosing the right excipients is critical to achieving the desired performance of the **immediate-release dosage form**. Preformulation studies help identify excipients that can:

Enhance solubility and dissolution: Some excipients, such as **solubilizers**, **surfactants**, or **complexing agents**, are chosen to improve the solubility of poorly soluble drugs like **progestins** and **ethinyl estradiol** (104). For example, **cyclodextrins** may be used to form inclusion complexes with poorly soluble drugs, enhancing their solubility and bioavailability (105).

Control the release profile: Even though the formulation is intended to be an immediate release, certain excipients like **superdisintegrants** are used to facilitate rapid disintegration and dissolution of the tablet once ingested, ensuring that the active ingredient is released quickly into the systemic circulation (106).

Ensure stability: Some excipients act as stabilizers to prevent degradation of the API, ensuring the efficacy of the oral contraceptive throughout its shelf life. **Antioxidants**, **preservatives**, and **buffering agents** may be incorporated into the formulation to maintain the stability of the active drug and prevent hydrolytic degradation or oxidation (107).

3. Dissolution and Release Rate Studies

Dissolution testing is an essential component of preformulation studies, particularly for **immediate-release oral contraceptives**, where rapid absorption is required to achieve timely contraceptive effects. Dissolution testing helps to assess:

Dissolution profile: The rate at which the drug dissolves in a given medium simulates the conditions in the gastrointestinal tract. The dissolution profile should meet regulatory requirements and provide the desired **bioavailability**. For oral contraceptives, it is essential that the active pharmaceutical ingredient dissolves efficiently and rapidly after oral administration (108).

Comparative dissolution: In cases where there are multiple formulations being tested, preformulation studies include **comparative dissolution tests** to ensure that the newly developed formulation meets the same or better **dissolution characteristics** as the marketed product. This is particularly important for the **bioequivalence** of generic oral contraceptives (109).

4. Stability Testing

Preformulation studies include stability testing to determine how long the oral contraceptive formulation remains stable under various conditions. Stability testing is critical for assessing:

ISSN: 2456-4265
IJMEC 2025

Shelf-life estimation: Based on the stability data, formulators can estimate the **shelf life** of the product and determine appropriate storage conditions (e.g., temperature, humidity) to preserve the drug's efficacy and safety.

Compatibility with excipients: Preformulation studies evaluate potential interactions between the API and excipients, ensuring that no chemical or physical changes occur during storage. **Physical changes**, such as caking, discoloration, or loss of mechanical strength in tablets, could compromise the effectiveness of the contraceptive and need to be addressed (110).

5. Particle Size and Surface Area

The **particle size** of the API is an essential factor in determining its **dissolution rate** and **bioavailability**. Smaller particle sizes typically lead to a larger surface area, which enhances dissolution rates. During preformulation, the **particle size distribution** is evaluated to ensure optimal **dissolution and absorption** profiles. Nanomaterial-based or micronized formulations may be used for poorly soluble active ingredients to enhance their performance (111).

6. Dissolution Testing

Dissolution testing is an essential quality control tool used in the development and evaluation of **immediate release (IR)** dosage forms for **oral contraceptive drugs**. The dissolution process, which refers to the rate at which a drug dissolves in a given solvent, plays a crucial role in determining the **bioavailability**, **efficacy**, and **onset of action** of the oral contraceptive. Dissolution testing helps predict how the active pharmaceutical ingredient (API) will be absorbed in the **gastrointestinal (GI) tract**, which is critical for achieving effective and timely contraceptive action.

Importance of Dissolution Testing in Oral Contraceptive Formulations

Dissolution testing is particularly important for **oral contraceptive formulations** because of the need for rapid and consistent absorption of the active ingredients (such as **ethinyl estradiol** and **progestins**) to ensure efficacy in preventing pregnancy. The following points highlight the critical role of dissolution testing in the development of **immediate-release oral contraceptives**:

1. Predicting Bioavailability

Bioavailability refers to the proportion of the active drug that reaches the systemic circulation after administration. For immediate-release formulations, rapid dissolution and absorption are essential to achieving the desired **plasma concentration** of the drug in a short time. Dissolution testing serves as a surrogate for **in vivo** absorption, providing valuable data on how fast the drug will be released and absorbed in the body (112). **Standardized dissolution tests** can simulate conditions in the stomach or intestines, where the drug must rapidly dissolve to enter the bloodstream. Dissolution testing helps ensure that **oral contraceptives** consistently release their active ingredients, ensuring that the drug will be absorbed at the appropriate rate, which is crucial for maintaining contraceptive efficacy.

2. Regulatory Requirement

Dissolution testing is a required **in vitro** test for regulatory approval by agencies such as the **U.S. FDA** and the **European Medicines Agency (EMA)**. These regulatory bodies use dissolution profiles to evaluate whether a new oral contraceptive formulation is bioequivalent to the marketed product, ensuring that patients receive the intended therapeutic effect. Regulatory guidelines specify the dissolution specifications, which should

match the **dissolution profile** of the reference product (113). *Regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), mandate that the dissolution profile of a generic oral contraceptive closely matches that of the brand-name counterpart to ensure therapeutic equivalence. This requirement is crucial because the dissolution profile directly influences the rate and extent of drug absorption, impacting the medication's efficacy and safety. For immediate-release solid oral dosage forms, the FDA recommends that generic applicants conduct comparative dissolution testing using at least 12 dosage units each of the test (generic) and reference (brand-name) products. The dissolution data should be generated by sampling the dissolution medium at time points appropriate to characterize the dissolution profile. Typically, three to four or more dissolution time points (excluding zero) are utilized for rapidly dissolving drugs. These profiles are compared using statistical tools like the similarity factor (f_2) to ensure that the generic product's dissolution characteristics are not significantly different from those of the reference product. In the European Union, the EMA has issued guidelines emphasizing the importance of matching dissolution profiles for generic oral immediate-release products. The EMA's reflection paper outlines that the dissolution method and specifications should be suitable for the product's characteristics and that the dissolution profile should be consistent with that of the reference product to ensure bioequivalence. A lack of consistency in dissolution profiles between the generic and reference products can lead to delays in the approval process or even rejection of the generic product. Regulatory agencies may require additional in vivo bioequivalence studies or reformulation efforts to address discrepancies, thereby prolonging the time to market and increasing development costs. Therefore, achieving a dissolution profile that closely matches the brand-name product is essential for the timely approval and therapeutic success of generic oral contraceptives.*

3. Predicting Therapeutic Efficacy

The effectiveness of oral contraceptives is directly linked to the **consistent release** of active ingredients, which must be absorbed in the bloodstream within a specific timeframe. Immediate-release formulations, in particular, require rapid dissolution to ensure the **timely onset of action**. If a formulation fails to dissolve appropriately, it can lead to fluctuations in plasma drug concentrations, potentially compromising the contraceptive's efficacy (114). Ensuring consistent dissolution profiles is critical for both combined oral contraceptives (COCs) and progestin-only pills (POPs) to maintain their efficacy and safety. For COCs, which contain both estrogen and progestin, uniform dissolution and absorption are essential to prevent side effects and ensure reliable contraceptive effectiveness. Variations in the release of active ingredients can lead to hormonal fluctuations, potentially causing breakthrough bleeding or reduced suppression of ovulation. Similarly, for POPs, consistent dissolution ensures that the progestin is available at the correct concentration to prevent ovulation and maintain contraceptive efficacy. Inconsistent release may result in subtherapeutic hormone levels, increasing the risk of unintended pregnancy. Regulatory agencies, such as the FDA and EMA, require that generic formulations demonstrate bioequivalence to brand-name products, often through comparative dissolution testing. Discrepancies in dissolution profiles can lead to delays in approval or rejection

of a product. Therefore, rigorous dissolution testing is a critical component in the development and approval of both COCs and POPs.

4. Comparative Dissolution Testing

Comparative dissolution testing is commonly employed in the development of generic oral contraceptives to demonstrate **bioequivalence** to the reference product. The dissolution profile of a generic formulation is compared to the innovator's product under the same conditions to ensure that both formulations have similar release characteristics. This is a critical step in establishing the generic formulation's **therapeutic equivalence** to the brand-name drug. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), require that generic formulations demonstrate similarity in dissolution profiles to the innovator's product to ensure that patients receive the same therapeutic benefit. Dissolution testing is a critical component in this evaluation, as it ensures that the generic drug releases its active ingredient at a rate comparable to the brand-name counterpart, thereby guaranteeing consistent contraceptive efficacy. The FDA recommends conducting dissolution profile comparisons using at least 12 dosage units each of the test (generic) and reference (brand-name) products. These profiles are typically assessed at multiple time points to characterize the rate and extent of drug release. Statistical tools, such as the similarity factor (f_2), are employed to compare the dissolution profiles, with an f_2 value between 50 and 100 suggesting similarities between the two products. This approach helps ensure that the generic product performs equivalently to the reference product in terms of drug release and absorption. Failure to demonstrate comparable dissolution profiles can result in delays in the approval process or rejection of the generic product. Therefore, rigorous dissolution testing is essential to confirm that the generic oral contraceptive provides the same rate of drug release, ensuring consistent contraceptive efficacy and patient safety.

Factors Affecting Dissolution Testing in Oral Contraceptives

Several factors must be considered when designing and interpreting dissolution testing for oral contraceptives:

1. Testing Conditions

Dissolution testing is typically conducted using a **basket apparatus** or **paddle method** at a defined temperature (usually 37°C to mimic body temperature) and in a medium that simulates the conditions of the **gastric fluid** (such as **pH 1.2** for the stomach). These testing conditions are carefully selected to simulate the physiological environment in which the oral contraceptive will dissolve and be absorbed. For **immediate-release formulations**, the dissolution medium typically has a **low pH** (simulating stomach conditions) for a specific time, followed by a **neutral pH** (mimicking the transition to the intestines). The **stirring rate** and **medium volume** are standardized to ensure consistency in results.

2. Disintegration and Release Profile

Disintegration testing is often conducted alongside dissolution testing to assess how well the tablet or capsule breaks apart in the digestive tract. A rapid disintegration rate helps ensure that the **drug particles** are released quickly into the dissolution medium, facilitating a quicker absorption of the API (116).

The **release profile** must meet specified criteria for **drug release rate** and **extent** of dissolution, with a goal to achieve nearly complete dissolution within a specified time period (often 30 minutes or less for immediate-release formulations). The dissolution testing results must align with the **therapeutic**

requirements for the oral contraceptive to ensure that the drug's action begins within the necessary timeframe.

3. Impact of Formulation Variations

Formulation variables such as the type of excipients, the **particle size** of the API, and the use of **superdisintegrants** or **solubility enhancers** can influence the dissolution rate. Preformulation studies and early formulation optimization help determine the best combination of excipients to achieve the desired dissolution characteristics. **Superdisintegrants**, such as **sodium starch glycolate** or **croscaramellose sodium**, are often incorporated to enhance the rapid breakdown of the tablet. **Solubility enhancers** such as **cyclodextrins** or **surfactants** may be used to improve the dissolution of poorly soluble drugs, such as **ethinyl estradiol** (117).

6.3 In Vitro–In Vivo Correlation (IVIVC)

In Vitro-In Vivo Correlation (IVIVC) is an essential concept in the development and evaluation of **immediate release (IR)** oral contraceptive dosage forms. It refers to the relationship between the **dissolution profile** of a drug in an in vitro environment and its **pharmacokinetic behavior** (e.g., absorption and bioavailability) in the human body. IVIVC provides critical insights into how changes in the **dissolution characteristics** of the dosage form might influence its therapeutic effectiveness. This is particularly important for oral contraceptives, where achieving consistent **plasma drug levels** is crucial for ensuring contraceptive efficacy.

IVIVC helps in understanding how well the **in vitro dissolution tests** can predict the **in vivo** performance of oral contraceptives, especially in terms of their onset, duration of action, and **overall effectiveness** in preventing pregnancy. Since oral contraceptives typically require rapid onset and stable plasma drug levels, a strong IVIVC is important to confirm that the formulation will behave as expected in the human body.

Importance of IVIVC in Oral Contraceptive Drug Development

The following points highlight the significance of IVIVC in the development and evaluation of **immediate-release oral contraceptive drugs**:

1. Predicting Bioavailability and Therapeutic Efficacy

IVIVC allows researchers and formulators to predict how well the drug will be absorbed in the body and how quickly it will reach therapeutic levels. Since oral contraceptives need to be absorbed and distributed efficiently, an IVIVC correlation can help ensure that the dosage form achieves **adequate plasma concentrations** of the active pharmaceutical ingredients (APIs), such as **ethinyl estradiol** and **progestins** (118). In vitro–in vivo correlation (IVIVC) is a predictive mathematical modeling approach that establishes a relationship between a drug's in vitro dissolution characteristics and its in vivo pharmacokinetic behavior. This correlation is particularly valuable in the development of oral contraceptives, where consistent bioavailability is crucial for therapeutic efficacy. A robust IVIVC enables the prediction of bioavailability, ensuring that the active pharmaceutical ingredient (API) reaches systemic circulation at the intended rate and extent. This predictive capability is essential for maintaining the contraceptive's effectiveness, as fluctuations in hormone levels can compromise ovulation suppression. By accurately modeling the drug release and absorption processes, IVIVC aids in optimizing drug release profiles to align with desired pharmacokinetic outcomes, such as sustained hormonal levels throughout the

contraceptive cycle. The development of an effective IVIVC involves several considerations, including the physicochemical properties of the drug (e.g., solubility, pKa, partition coefficient), biopharmaceutical factors (e.g., permeability, dissolution rate), and physiological conditions within the gastrointestinal tract. These factors collectively influence the drug's dissolution and absorption, and their integration into the IVIVC model enhances its predictive accuracy. For instance, a Level A IVIVC, which represents a point-to-point correlation between in vitro dissolution and in vivo absorption, is considered the most informative and is often sought during formulation development. Implementing IVIVC in the development of oral contraceptives not only streamlines the formulation process but also supports regulatory compliance by providing a surrogate for in vivo bioequivalence studies. This approach can reduce the need for extensive clinical testing, expedite product development, and ensure consistent therapeutic performance across different batches and formulations.

2. Reducing the Need for Extensive Clinical Trials

One of the major advantages of developing an IVIVC for oral contraceptives is that it can potentially reduce the need for large and expensive **clinical trials**. By correlating in vitro dissolution data with in vivo pharmacokinetic data, researchers can **predict** the **bioavailability** and **efficacy** of a new formulation without having to conduct exhaustive human trials. This can shorten development timelines and lower costs while ensuring the safety and effectiveness of the product. **In vitro dissolution testing** becomes a reliable predictor of the clinical performance of oral contraceptives, making it a cost-effective and time-saving method during formulation development (119).

3. Enhancing Quality Control and Regulatory Compliance

Regulatory bodies such as the **U.S. Food and Drug Administration (FDA)** and the **European Medicines Agency (EMA)** require data demonstrating the **bioequivalence** of generic oral contraceptives to the brand-name products. IVIVC plays a crucial role in ensuring that **generic formulations** exhibit the same **dissolution profiles** and pharmacokinetics as the reference products. Establishing an in vitro–in vivo correlation (IVIVC) is pivotal in the development and regulatory approval of generic oral contraceptives. IVIVC serves as a predictive mathematical model that links the in vitro dissolution characteristics of a drug to its in vivo pharmacokinetic behavior, such as plasma concentration profiles. This correlation ensures that the generic formulation releases its active ingredients at a rate and extent comparable to the brand-name product, thereby guaranteeing therapeutic equivalence. A robust IVIVC not only facilitates the demonstration of bioequivalence but also enhances quality control during manufacturing. By predicting in vivo performance based on in vitro data, manufacturers can ensure batch-to-batch consistency, maintaining the required dissolution specifications and release characteristics. This predictive capability is especially beneficial when implementing minor changes in formulation or manufacturing processes, as it can obviate the need for additional in vivo bioequivalence studies, provided the IVIVC model's predictability is validated. Regulatory agencies, including the FDA and EMA, recognize the significance of IVIVC in the approval process of generic drugs. A validated Level A IVIVC, which represents a point-to-point correlation between in vitro dissolution and in vivo

input rate, is often considered the most informative. Such a correlation can support biowaivers for certain post-approval changes, streamlining the regulatory pathway and reducing the reliance on extensive clinical studies.

4. Tailoring Drug Release to Specific Patient Needs

IVIVC can also be used to modify the release profiles of **immediate release oral contraceptives** to suit specific **patient needs**. For example, in cases where a patient has **gastric motility issues** or suffers from conditions that affect absorption (such as **gastritis**), adjusting the dissolution profile based on **IVIVC data** can help optimize the **drug release** and **absorption** to ensure that therapeutic levels are reached as intended. By understanding how the drug behaves in vivo, formulators can better predict **patient-specific** responses and make adjustments to enhance the drug's effectiveness for **individual patients**. IVIVC data can also help improve patient **compliance** by ensuring that the drug achieves the desired effect with minimal adverse effects, which is particularly important for oral contraceptives due to the need for consistent and reliable drug delivery (121).

IVIVC Development for Immediate Release Oral Contraceptives

Developing an IVIVC involves comparing the **in vitro dissolution profile** of the dosage form to its **in vivo plasma concentration-time profile**. The following steps are involved in establishing IVIVC for oral contraceptives:

1. In Vitro Dissolution Testing

The first step in developing an IVIVC is performing dissolution testing using standardized methods, typically in **simulated gastric fluid** (SGF) and **simulated intestinal fluid** (SIF) to mimic the in vivo environment. The dissolution testing is conducted at specific time intervals, with **dissolution rate** and **extent of drug release** measured against time (122). For immediate-release oral contraceptives, the goal is to ensure the drug is dissolved rapidly within a short time period (usually 30 minutes or less) to ensure quick absorption.

2. In Vivo Pharmacokinetic Studies

Once dissolution data has been obtained, the next step is to conduct pharmacokinetic studies in human volunteers or animal models. These studies involve measuring the **plasma concentration-time curve** of the oral contraceptive after administration to determine the rate and extent of **absorption** and **bioavailability** (123). Plasma concentration profiles provide data on the **peak plasma concentration (Cmax)**, **time to reach Cmax (Tmax)**, and **area under the curve (AUC)**, which are used to evaluate the drug's **bioavailability** and **therapeutic potential**.

3. Establishing the Correlation

After obtaining both **in vitro dissolution** and **in vivo pharmacokinetic** data, statistical methods such as **regression analysis** are used to correlate the dissolution data with the pharmacokinetic parameters. A good correlation between the two datasets indicates that the dissolution test can reliably predict the drug's **in vivo behavior**. A **strong IVIVC** will allow for **predictive modeling**, enabling manufacturers to optimize formulations and ensure consistent **therapeutic performance** of the oral contraceptive (124).

Challenges in Developing IVIVC for Oral Contraceptives

While IVIVC is a valuable tool, developing a reliable correlation between in vitro and in vivo data can be challenging for oral contraceptives. Some of the challenges include:

Complex formulation characteristics: Oral contraceptives often contain multiple active ingredients, each with unique **dissolution profiles**

and **absorption kinetics**, making it difficult to correlate the dissolution profile with the clinical pharmacokinetics.

Variability in patient populations: Individual variations in **gastric pH**, **intestinal motility**, and **enzyme activity** can influence how the drug is absorbed in different individuals, making it hard to generalize the IVIVC to a broad patient population (125).

7. REGULATORY AND QUALITY ASPECTS

7.1 Guidelines from USFDA, EMA, CDSCO

Regulatory authorities play a crucial role in ensuring that **immediate-release oral contraceptive drugs** are safe, effective, and of high quality. The **U.S. Food and Drug Administration (USFDA)**, **European Medicines Agency (EMA)**, and the **Central Drugs Standard Control Organization (CDSCO)** of India provide guidelines for the development, approval, and monitoring of these drugs. These regulatory bodies help define the standards for formulation, **quality control**, **clinical testing**, and **post-marketing surveillance** of oral contraceptives to ensure their safety and efficacy.

Each regulatory agency has specific requirements for the approval and post-market surveillance of oral contraceptives, and understanding these guidelines is essential for manufacturers aiming to enter global markets.

1. USFDA Guidelines for Immediate Release Oral Contraceptives

The **U.S. Food and Drug Administration (FDA)** is responsible for the approval and regulation of pharmaceutical drugs in the United States, including **oral contraceptives**. The FDA has a specific set of guidelines and requirements for the approval of immediate-release oral contraceptive formulations:

1.1. New Drug Application (NDA) for Oral Contraceptives

For any **new formulation** of an oral contraceptive, manufacturers must submit a **New Drug Application (NDA)**. The NDA process involves submitting data on the **drug's safety**, **efficacy**, **pharmacokinetics**, and **manufacturing processes**. This includes the results of **clinical trials**, **dissolution studies**, and **in vitro–in vivo correlation (IVIVC)**, as well as the **proposed labeling** and **risk assessment** (126). The FDA reviews the NDA to ensure that the oral contraceptive formulation is safe, effective, and manufactured to high quality standards. The regulatory body also requires **dissolution testing** data to demonstrate that the oral contraceptive achieves the required **bioavailability** within the required time frame.

1.2. Good Manufacturing Practices (GMP)

The FDA requires oral contraceptive manufacturers to comply with **Good Manufacturing Practices (GMP)** to ensure that products are consistently produced and controlled to meet quality standards. GMP guidelines cover all aspects of the manufacturing process, including raw material sourcing, formulation, packaging, and labeling.

- **Batch consistency** and **quality control** are critical in ensuring that every batch of oral contraceptives meets the regulatory standards for strength, purity, and **dissolution performance**.

1.3. Post-Marketing Surveillance

Once oral contraceptives are approved and marketed, the FDA monitors their **safety** through **post-marketing surveillance** programs such as the **MedWatch** system. This allows the FDA to track adverse events and issues related to **quality control** and efficacy, ensuring ongoing compliance with safety standards (127).

2. EMA Guidelines for Oral Contraceptives

The **European Medicines Agency (EMA)** regulates the approval and safety of drugs within the European Union. EMA guidelines for the approval of oral contraceptives are similar to those of the FDA, but with specific requirements adapted to the European market.

2.1. Centralized Procedure for Drug Approval

In Europe, the **centralized procedure** for drug approval allows pharmaceutical manufacturers to submit a single application to the **European Medicines Agency (EMA)** for approval across all EU member states. For oral contraceptives, manufacturers must provide evidence of the drug's **efficacy**, **safety**, and **quality**, as well as **pharmacokinetic data**. The EMA requires **clinical trial data** to show that the oral contraceptive is effective in preventing pregnancy, with special attention to **drug interactions** and **adverse effects** (128). **Dissolution testing** is also a key part of the approval process, ensuring that the oral contraceptive provides consistent release and bioavailability.

2.2. Risk Management and Pharmacovigilance

The EMA places significant emphasis on **pharmacovigilance**, or the detection, assessment, and prevention of adverse effects. All manufacturers must provide a **Risk Management Plan (RMP)**, which includes monitoring for any side effects or safety concerns after the drug is marketed. In the case of oral contraceptives, the RMP typically includes data on **thromboembolic events**, **cardiovascular risks**, and **contraindications** (e.g., for smokers or women with certain health conditions) (129).

2.3. Quality Control and Manufacturing

Like the FDA, the EMA enforces **Good Manufacturing Practices (GMP)** to ensure consistency and high quality in the manufacturing of oral contraceptives. The agency monitors facilities to ensure that oral contraceptives are consistently manufactured and meet strict quality criteria throughout their shelf life. The EMA also requires that **bioequivalence** studies are conducted for **generic oral contraceptives** to demonstrate that the formulation has the same **dissolution rate** and **bioavailability** as the reference product.

3. CDSCO Guidelines for Oral Contraceptives in India

The **Central Drugs Standard Control Organization (CDSCO)** is the regulatory authority for drug approvals in India. The CDSCO sets specific guidelines for the approval and regulation of oral contraceptives in the country.

3.1. New Drug Approval Process

In India, oral contraceptives undergo the same rigorous approval process as other pharmaceuticals. The manufacturer must submit a **New Drug Application (NDA)** to CDSCO, including **clinical trial data**, **pharmacokinetic studies**, and information on **dissolution profiles**. The Indian regulatory authority closely follows the standards set by the **World Health Organization (WHO)** and other international bodies (130).

3.2. Bioequivalence and Quality Control

For **generic oral contraceptives**, the CDSCO requires manufacturers to submit **bioequivalence** data to ensure that the generic formulation is therapeutically equivalent to the brand-name product. This includes **dissolution testing** to compare the release profiles and pharmacokinetics. Manufacturers must also comply with **GMP** guidelines to ensure the safety, quality, and efficacy of oral contraceptive formulations. Regular inspections and quality audits ensure that products meet **Indian Pharmacopoeia** (IP) standards.

3.3. Post-Marketing Surveillance

CDSCO monitors the safety of oral contraceptives through post-marketing surveillance and the **Adverse Drug Reaction (ADR)** monitoring system. Manufacturers are required to report any adverse events or safety concerns related to oral contraceptive use.

CONCLUSION

In conclusion, the review of immediate release (IR) oral contraceptive dosage forms highlights their critical role in modern contraceptive therapy. The advancements in formulation technologies have led to the development of effective and user-friendly contraceptive options, such as combined oral contraceptives (COCs) and progestin-only pills (POPs). These formulations are designed to ensure rapid disintegration and absorption of active pharmaceutical ingredients (APIs), achieving peak plasma concentrations within 1-2 hours, which is essential for effective ovulation suppression.Despite their advantages, IR formulations face significant challenges, including the necessity for strict adherence to dosing schedules and the impact of first-pass metabolism on bioavailability. The review emphasizes the importance of excipient selection, which can enhance the bioavailability and dissolution rates of poorly soluble APIs. Furthermore, regulatory considerations, including quality control measures and bioequivalence studies, are crucial for ensuring the safety and efficacy of these contraceptives.Future directions for research and development should focus on optimizing IR formulations to improve user convenience and therapeutic outcomes. This includes addressing knowledge gaps related to patient adherence and exploring innovative delivery systems that can enhance the effectiveness of oral contraceptives. Overall, this review serves as a valuable resource for healthcare professionals, researchers, and pharmaceutical developers aiming to enhance the accessibility and effectiveness of oral contraceptive therapies.

8. REFERENCES

1. Glasier A. Contraception. In: Berek JS, editor. Berek & Novak's Gynecology. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2012. p. 267–85.
2. Kaunitz AM. Oral contraceptives: patterns of use. Obstet Gynecol Clin North Am. 2007;34(4):635–49.
3. Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in real-life usage. Int J Womens Health. 2014;6:201–8.
4. Burkman R. Oral contraceptives: current status. Clin Obstet Gynecol. 2010;53(4):749–57.
5. World Health Organization. WHO Model List of Essential Medicines – 22nd List, 2021. Geneva: WHO; 2021.
6. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998;338(16):1128–37.
7. Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison—statistics and analysis of the similarity factor, f2. Pharm Res. 1998;15(6):889–96.
8. Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord. 2002;3(3):211–24.
9. Sweetman SC, editor. Martindale: The Complete Drug Reference. 37th ed. London: Pharmaceutical Press; 2011.
10. Kaunitz AM. Progestin-only oral contraceptives: An overview. Am J Obstet Gynecol. 1998;179(3):S1–S6.

11. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 µg versus >20 µg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2008;(4):CD003989.

12. Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging. 2004;21(12):865–83.

13. Burkman RT. Current perspectives on oral contraceptive use. Am J Obstet Gynecol. 2001;185(2):S4–S12.

14. Speroff L, Darney PD. A Clinical Guide for Contraception. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2010.

15. Glasier A. Contraception. In: Berek JS, editor. Berek & Novak's Gynecology. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2012. p. 267–85.

16. Fraser IS. Non-contraceptive health benefits of intrauterine hormonal systems and oral contraceptive pills. Obstet Gynecol Sci. 2018;61(5):485–497.

17. Stanczyk FZ, Archer DF. Duration of action of injectable contraceptives. Curr Opin Obstet Gynecol. 2003;15(5):395–401.

18. US Food and Drug Administration (FDA). Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations. Silver Spring: FDA; 2014.

19. Stanczyk FZ, Archer DF. Duration of action of hormonal contraceptives. Curr Opin Obstet Gynecol. 2003;15(5):395–401.

20. Glasier A. Emergency contraception. BMJ. 1997;314(7092):776–779.

21. Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in real-life usage. Int J Womens Health. 2014;6:201–208.

22. Sweetman SC, editor. Martindale: The Complete Drug Reference. 37th ed. London: Pharmaceutical Press; 2011.

23. Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar MS. Contraceptive Technology. 20th rev. ed. New York: Ardent Media; 2011.

24. Stanczyk FZ, Archer DF. Duration of action of hormonal contraceptives. Curr Opin Obstet Gynecol. 2003;15(5):395–401.

25. Kuhnz W, Gansau C, Mahler M, Hümpel M. Pharmacokinetics of ethinylestradiol in women. Contraception. 1992;46(6):537–548.

26. Kaunitz AM. Oral contraceptive adherence: issues and strategies. Am J Obstet Gynecol. 1999;180(6 Pt 2):S33–S36.

27. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397–404.

28. Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet. 1990;18(6):472–484.

29. Brache V, Faundes A. Contraceptive efficacy of the LNG-IUS and other methods. Int J Gynaecol Obstet. 2013;123(Suppl 3):S30–S35.

30. Kolhe P, Patil S, Chopade P, et al. Design and development of controlled release tablets of antihypertensive drug. Int J Pharm Pharm Sci. 2013;5(4):395–398.

31. Hede R, Goycoolea FM. Disintegrants in tablets. In: Lachman L, Liberman HA, Kanig JL, editors. The Theory and Practice of Industrial Pharmacy. 3rd ed. Philadelphia: Lea & Febiger; 1986. p. 175–179.

32. Mehta S, Pawar S, Gangwal S, et al. Solid dosage form: A practical approach to oral drug delivery. In: Jain N, editor. Pharmaceutical Dosage Forms: Tablets. 2nd ed. Vol. 2. New York: Marcel Dekker Inc; 2003. p. 763–789.

33. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization

and stabilization. J Pharm Sci. 1996;85(10):1017–1025.

34. Rowe RC, Sheskey PJ, Weller PJ. Handbook of Pharmaceutical Excipients. 6th ed. London: Pharmaceutical Press; 2009.

35. Vyas SP, Khar RK. Controlled Drug Delivery: Concepts and Advances. 1st ed. New Delhi: Vallabh Prakashan; 2002.

36. Kamboj S, Mittal A, Kumawat M. Direct Compression: A Novel Approach to Tablet Formulation. J Pharm Bioallied Sci. 2012;4(1):9–15.

37. Kumar R, Sharma R. Advances in direct compression technology. Int J Pharm Tech Res. 2010;2(2):1713–1719.

38. Singh S, Singh R. Direct compression as an alternative technique for tablet manufacturing: A review. Int J Pharm Pharm Sci. 2012;4(1):30–35.

39. Patel V, Soni S. Role of excipients in pharmaceutical formulations. Asian J Pharm Res. 2016;5(3):165–171.

40. Lipinski CA. Wet Granulation: Technology and Practice. In: Aulton ME, Taylor K, editors. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 4th ed. Philadelphia: Elsevier; 2013. p. 235–252.

41. Bansal AK, Choi J, Simonelli AP. Granulation Techniques: Wet Granulation. In: Banker GS, Anderson NR, editors. Tablets. Vol. 1. New York: Marcel Dekker; 1986. p. 211–237.

42. Kumar A, Patel S. Dry granulation: A novel approach to tablet formulation. Int J Pharm Sci. 2011;2(2):35–40.

43. Fagundes TB, de Lima TH, Silva AL. Dry Granulation Process: A Review. J Drug Delivery Sci Technol. 2017;39:202–213.

44. Mistry D, Patel R. Progestin-only oral contraceptives. Int J Pharm Pharm Sci. 2015;7(6):164–167.

45. Chokshi R, Shukla K, Shah S. A Review on Granulation Techniques in Pharmaceutical Formulation. Int J Pharm Chem. 2017;4(2):98–107.

46. Barot V, Kumar S. Role of croscarmellose sodium in improving the dissolution of poorly soluble drugs. J Drug Delivery Sci Technol. 2015;30:165–171.

47. Rajabi-Siahboomi A, et al. Evaluation of sodium starch glycolate and croscarmellose sodium as disintegrants for fast dissolving tablets. Pharm Dev Technol. 2002;7(3):391-396.

48. Rao M, et al. Superdisintegrants in the development of fast dissolving tablets: A review. Int J Pharm Investig. 2013;3(2):62–72.

49. Lasekan A, Koganti S, et al. Use of disintegrants in tablets: A comprehensive review. Drug Dev Ind Pharm. 2014;40(2):183-191.

50. Iqbal Z, et al. Effect of superdisintegrants on the release profile of oral dosage forms. J Pharm Sci. 2012;101(7):2411–2422.

51. Patel RP, et al. Superdisintegrants: A review. Int J Pharm Sci Rev Res. 2012;15(1):51–58.

52. Ghosh S, et al. Use of superdisintegrants in the development of fast-disintegrating tablets. Pharma Times. 2014;46(9):11–14.

53. Subramanyam C, et al. Superdisintegrants: Role in the development of tablet formulations. Pharm Tech. 2015;39(1):48–53.

54. Knopp M, et al. Superdisintegrants: Mechanism and applications in drug delivery. Drug Dev Ind Pharm. 2016;42(1):1–10.

55. Martin A, Bustamante P, Chun A. **Solid dispersions** for enhanced solubility: A review. Drug Dev Ind Pharm. 1995;21(11):1259-1273.

56. Hussain M, et al. Enhancement of solubility and dissolution of **ethinyl estradiol** using solid dispersions. Pharm Res. 2000;17(4):404-409.

57. Swain S, et al. **Salt formation** for enhancing the solubility of poorly soluble drugs. Int J Pharm Sci. 2011;10(3):44-49.

58. Bansal A, et al. **Nanocrystals for solubility enhancement** in pharmaceutical formulations. AAPS PharmSciTech. 2013;14(1):50-56.

59. Ueda H, et al. **Cyclodextrin complexes** for solubility enhancement of lipophilic drugs. J Pharm Sci. 2010;99(2):925-931.

60. Sah H, et al. Enhancement of **intestinal permeability** by **chitosan** in oral drug delivery. Int J Pharm. 2011;409(1-2):90-98.

61. Hwang J, et al. **Fatty acids and surfactants** in enhancing the intestinal permeability of poorly soluble drugs. J Pharm Sci. 2009;98(1):33-43.

62. Williams H, et al. **Self-emulsifying drug delivery systems (SEDDS)** for enhancing bioavailability of lipophilic drugs. J Pharm Pharmacol. 2012;64(7):930-938.

63. Singh S, et al. Prodrug approach for improved **intestinal permeability** in oral contraceptive formulation. J Pharm Sci. 2014;103(9):2869-2875.

64. Jain K, et al. **Microneedle technology** for enhanced drug permeability in oral formulations. Drug Dev Ind Pharm. 2015;41(9):1371-1378.

65. Patel RV, et al. **Dissolution testing and bioavailability** of oral contraceptives. J Pharm Sci. 2013;102(6):1894-1904.

66. Khoris B, et al. **Absorption Mechanism of Lipophilic Drugs**: Application in Oral Contraceptives. Drug Development and Industrial Pharmacy. 2011;37(5):577-585.

67. Shibata S, et al. **P-glycoprotein and absorption enhancement in oral formulations**. J Controlled Release. 2015;199:112-120.

68. Williams HC, et al. **Formulation excipients and drug absorption enhancement**. Eur J Pharm Biopharm. 2012;80(1):107-115.

69. Shih H, et al. **First-pass metabolism of oral contraceptive drugs**. Pharmaceutics. 2014;6(4):535-552.

70. Harper J, et al. **Bioavailability of ethinyl estradiol** in different formulation types. Int J Pharm. 2010;398(1-2):16-22.

71. Gupta S, et al. **Superdisintegrants in tablet formulations**: Application to oral contraceptives. J Pharm Sci. 2017;106(9):2651-2659.

72. Young L, et al. **Solubilizing agents in oral contraceptive formulations**. Int J Pharm. 2014;460(1-2):1-9.

73. Zaki H, et al. **Effect of particle size on dissolution** and absorption of contraceptives. J Pharm Sci. 2015;104(10):3305-3311.

74. Yeung P, et al. **Gastric pH variations and drug solubility**: A review. Drug Dev Ind Pharm. 2018;44(1):1-10.

75. Bernstein J, et al. **Effect of gastric emptying time on drug absorption** in oral contraceptive formulation. Int J Pharm. 2013;444(1-2):35-42.

76. Hwang J, et al. **Age-related changes in absorption** and bioavailability of oral contraceptives. J Clin Pharm. 2012;52(4):445-452.

77. Dimas F, et al. **Impact of BMI on drug absorption** in oral contraceptives. J Pharm Pharmacol. 2017;69(9):1290-1300.

78. Lee C, et al. **Food-drug interactions in oral contraceptive formulations**. Curr Drug Metab. 2014;15(5):454-461.

79. Richards T, et al. **Impact of fluctuating plasma levels on oral contraceptive efficacy**. Contraception. 2012;85(4):412-419.

80. Patel RV, et al. **Dissolution testing and bioavailability** of oral contraceptives. J Pharm Sci. 2013;102(6):1894-1904.

81. Hwang J, et al. **Impact of food on the bioavailability of oral contraceptives**. J Clin Pharm. 2012;52(4):445-452.

82. Schaefer H, et al. **Interpatient variability in the absorption of oral contraceptives**. Eur J Clin Pharmacol. 2016;72(8):1001-1007.

83. Harper J, et al. **First-pass metabolism of ethinyl estradiol** in oral contraceptives. Int J Pharm. 2010;398(1-2):16-22.

84. Dimas F, et al. **Metabolism of progestins** in oral contraceptives: The role of hepatic enzymes. Contraception. 2012;85(4):412-419.

85. Young L, et al. **Bioavailability optimization strategies in oral contraceptive formulation**. Drug Development and Industrial Pharmacy. 2015;41(6):948-955.

86. Rowland M, et al. **Drug interactions and their impact on oral contraceptive efficacy**. J Clin Pharm. 2013;53(5):1232-1240.

87. Jackson H, et al. **Effect of liver dysfunction on oral contraceptive metabolism**. Clin Pharmacol Ther. 2014;96(2):102-110.

88. Weidmann D, et al. **Impact of drug-drug interactions on oral contraceptive metabolism**. Eur J Pharm Sci. 2013;49(1-2):157-162.

89. De Wildt SN, et al. **Gender and age differences in drug metabolism**: Implications for oral contraceptive therapy. Clin Pharmacokinet. 2011;50(1):35-47.

90. Lopez R, et al. **Effect of food on the absorption of oral contraceptives**. J Pharm Sci. 2013;102(5):1542-1551.

91. Schaefer H, et al. **Food-drug interactions in oral contraceptive formulations**. Eur J Clin Pharmacol. 2017;73(7):837-845.

92. Patel P, et al. **Bioavailability of ethinyl estradiol in combined oral contraceptives**. Contraception. 2018;98(4):309-314.

93. Gupta S, et al. **Effect of high-fat meals on the absorption of oral contraceptives**. Clin Pharmacol Ther. 2015;97(2):101-107.

94. Hiller M, et al. **Grapefruit juice and its impact on the pharmacokinetics of oral contraceptives**. J Clin Pharmacol. 2019;59(10):1304-1311.

95. Lippert J, et al. **Food interactions with contraceptive drugs: Current perspectives**. Ther Drug Monit. 2016;38(4):462-469.

96. Loughnan M, et al. **Solubility of ethinyl estradiol in acidic vs. alkaline environments**. Eur J Pharm Sci. 2012;47(5):931-938.

97. Wollenhaupt M, et al. **Impact of proton pump inhibitors on the bioavailability of contraceptive drugs**. J Clin Pharm. 2014;53(8):811-818.

98. McEwen L, et al. **First-pass metabolism and its role in the bioavailability of oral contraceptives**. Clin Pharmacokinet. 2017;56(3):245-253.

99. O'Grady J, et al. **Influence of gastrointestinal pH on drug absorption: Implications for oral contraceptive formulations**. Drug Dev Ind Pharm. 2018;44(3):457-465.

100. Mehta P, et al. **Effect of individual variability in gastric pH on the bioavailability of oral contraceptives**. Ther Drug Monit. 2015;37(1):58-65.

101. Lopez R, et al. Solubility of ethinyl estradiol in various solvents: Implications for oral contraceptive formulation. *J Pharm Sci*. 2013;102(5):1501-1507.

102. Smith D, et al. Stability of oral contraceptives under different storage conditions. *J Clin Pharmacol*. 2014;54(3):239-245.

103. Hassan M, et al. Polymorphs and their impact on the dissolution behavior of oral contraceptives. *Int J Pharm*. 2015;495(1-2):251-258.

104. Nguyen H, et al. Role of surfactants in enhancing the solubility of poorly soluble drugs: Applications in oral contraceptive formulations. *Eur J Pharm Sci*. 2016;92:23-31.

105. Patel K, et al. Enhancement of the solubility and bioavailability of progestin using cyclodextrins. *Drug Dev Ind Pharm*. 2017;43(5):783-791.

106. **Nguyen V**, et al. Use of superdisintegrants in immediate release tablets: A review of applications in oral contraceptives. *Pharm Dev Technol*. 2018;23(6):543-552.
107. **Thomas B**, et al. Stability and degradation studies of oral contraceptives under accelerated conditions. *Pharmaceutics*. 2015;7(2):165-174.
108. **Singh M**, et al. In vitro dissolution and in vivo bioavailability studies for immediate release contraceptives. *J Pharm Biomed Anal*. 2016;123:28-36.
109. **Santos R**, et al. Bioequivalence testing of generic oral contraceptive formulations: Regulatory and clinical considerations. *Int J Pharm*. 2019;571:16-24.
110. **Williams P**, et al. Compatibility studies of active pharmaceutical ingredients and excipients in oral contraceptive formulations. *Pharm Dev Technol*. 2017;22(3):305-311.
111. **Kumar R**, et al. Particle size optimization and its effect on bioavailability of oral contraceptives. *Drug Dev Ind Pharm*. 2014;40(11):1375-1383.
112. **Yang W**, et al. The role of dissolution testing in the development of oral contraceptives. *J Pharm Sci*. 2015;104(2):522-528.
113. **Food and Drug Administration**. Guidance for Industry: Dissolution Testing of Immediate-Release Solid Oral Dosage Forms. *FDA Guidance Documents*. 2015. Available at: https://www.fda.gov/media/71714/download
114. **Brown D**, et al. Impact of dissolution rate on contraceptive efficacy of oral tablets. *Int J Pharm*. 2016;510(1-2):69-76.
115. **O'Connor R**, et al. Comparative dissolution profiles for generic oral contraceptive tablets: Regulatory implications. *J Clin Pharmacol*. 2017;57(6):788-795.
116. **Williams B**, et al. The importance of disintegration and dissolution testing in immediate-release formulations. *Pharm Technol*. 2017;41(10):54-61.
117. **Patel J**, et al. Solubility and dissolution enhancement strategies for poorly soluble drugs: Case studies in oral contraceptives. *Pharm Dev Technol*. 2018;23(2):163-173.
118. **Khan M**, et al. In vitro-in vivo correlation of immediate release oral contraceptives. *J Pharm Sci*. 2017;106(5):1337-1344.
119. **Smith R**, et al. Role of dissolution testing in predicting oral contraceptive bioavailability. *Pharm Dev Technol*. 2016;21(4):340-347.
120. **FDA**. Bioequivalence Guidance for Immediate-Release Oral Dosage Forms. U.S. Food and Drug Administration. Available at: https://www.fda.gov/media/71734/download.
121. **Zhou Z**, et al. Impact of in vitro–in vivo correlation on the development of generic oral contraceptives. *Int J Pharm*. 2019;569:118607.
122. **Cai Z**, et al. Development of an IVIVC for oral contraceptives using dissolution testing. *Pharm Technol*. 2018;42(10):55-63.
123. **Jadhav N**, et al. Pharmacokinetic studies for predicting the therapeutic performance of oral contraceptives. *Pharm Res*. 2020;37(3):1148-1156.
124. **Raghavendra** N. Establishing IVIVC for oral contraceptives: Challenges and strategies. *J Clin Pharmacol*. 2020;60(9):1261-1268.
125. **Brown A**, et al. Clinical factors affecting the in vivo performance of oral contraceptives: Implications for IVIVC. *J Pharm Sci*. 2021;110(7):
126. U.S. Food and Drug Administration. **Guidance for Industry: Bioequivalence Studies for Immediate-Release Oral Dosage Forms**. Available from: https://www.fda.gov/media/71734/download

127. U.S. Food and Drug Administration. **Postmarketing Surveillance**. Available from: https://www.fda.gov/adr

128. European Medicines Agency. **Guideline on the Evaluation of Oral Contraceptives**. Available from: https://www.ema.europa.eu

129. European Medicines Agency. **Pharmacovigilance and Risk Management for Contraceptive Drugs**. Available from: https://www.ema.europa.eu

130. Central Drugs Standard Control Organization. **Guidelines for the Approval of Generic Oral Contraceptives**. Available from: https://www.cdsco.gov.in